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the enzymatic partnering of these two molecules. In both cases, proximity of these co-factors on the
surface of the endothelial membrane appears to be the key variable and has significant implications,
affecting not only functional activity in vitro but therapeutic efficacy in vivo. These findings underscore the
complexity of targeting biotherapeutics to the plasmalemma, and suggest that precision on a nanometer
scale is necessary for optimal biotherapeutic effect.
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ABSTRACT
AUGMENTING THE PROTEIN C PATHWAY WITH ENDOTHELIAL TARGETED
BIOTHERAPEUTICS: STRATEGIES TO PROMOTE PARTNERING OF TM AND EPCR
Dr. Colin F. Greineder
Dr. Vladimir R. Muzykantov
The design of targeted recombinant biotherapeutics is a rapidly growing area of
translational biomedical research, with particular relevance to acute and lifethreatening conditions, in which the available treatment options have narrow
therapeutic indices. Although vascular immunotargeting typically has been
thought of as a strategy for controlling and altering pharmacokinetics, in the
context of biotherapeutic delivery, precise localization may be the primary goal,
allowing optimal interaction of drug with endogenous partners. The protein C
pathway has important protective roles in a variety of human illnesses, including
sepsis and acute lung injury. We recently reported a strategy for augmenting this
pathway by anchoring thrombomodulin (TM, CD141) to the endothelium via an
affinity ligand to platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31).
Endothelial PECAM-1, however, is believed to localize to a different portion of the
cell membrane than the majority of endogenous TM and its key co-factor, the
endothelial protein C receptor (EPCR, CD201). The current document includes
new data indicating that recombinant TM anchored to endothelial PECAM-1 does
not partner effectively with EPCR and describes the design, implementation, and
validation of two strategies for more effectively replicating the enzymatic
partnering of these two molecules. In both cases, proximity of these co-factors
on the surface of the endothelial membrane appears to be the key variable and
has significant implications, affecting not only functional activity in vitro but
therapeutic efficacy in vivo. These findings underscore the complexity of
targeting biotherapeutics to the plasmalemma, and suggest that precision on a
nanometer scale is necessary for optimal biotherapeutic effect.
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CHAPTER ONE: INTRODUCTION
I. A Brief review of Drug Targeting
Over the past four decades, thousands of scientists and clinicians have
contributed to the study of drug targeting, resulting in the development and
testing of hundreds of strategies for the delivery of therapeutics to various
locations in the body.

By the late 1990s, annual sales of Advanced Drug

Delivery Systems (ADDS) in the United States exceeded $10 billion, and they
have continued to rise rapidly1. While a comprehensive survey of the field is
clearly beyond the scope of this document, it is instructive to briefly review the
origins of drug targeting and its progression from the controlled release of small
lipophilic drugs to the precise subcellular localization of macromolecular
biotherapeutics.

Magischen Kugeln: the origins of targeted drug delivery
With few exceptions, the pharmaceuticals in clinical use distribute
throughout the body based on their physical characteristics (size, charge,
lipophilicity, etc.) and the physiologic state of the patient to which they are
administered. Without any specific control over pharmacokinetics, most drugs do
not accumulate at their intended site of therapeutic action. In order to achieve
adequate concentration at the required location, large doses, repeated
administration, or even continuous infusion may be required, increasing the cost,
risk of harmful side-effects, and likelihood that patients will not adhere to the
proper regimen. Far from theoretical, these factors lead to the failure of the
majority of prospective therapeutics2,3, as well as millions of dollars of annual
health care expenses related to adverse drug events and medication noncompliance4,5.

With the development of monoclonal antibodies (mAbs) and

advances in polymeric chemistry in the 1970s, a new field of scientific
investigation emerged, dedicated to the development of delivery systems for the
1

controlled release, distribution, and permeation of drugs across cellular
membranes6.
The basic concepts of drug targeting were formulated long before any
technology existed to apply them to biological systems. The Nobel laureate, Paul
Ehrlich, is largely credited with advancing the theory of Seitenketten (“side
chains”), or cellular receptors, in the early 20th century7. He postulated that these
receptors were responsible for the binding of bacterial toxins to particular cells –
e.g. the attachment of tetanospasmin to the neuromuscular junction8. Ehrlich
went on coin the famous term magischen Kugeln (“magic bullets”) to refer to
therapeutics that would mimic the action of these toxins, going directly to their
intended cellular targets and attacking diseased tissue while inflicting no harm to
the remainder of the body9. While Ehrlich’s vision has yet to be fully realized,
substantial progress has been made, with the design and implementation of
hundreds of ADDS. Research efforts have followed a natural progression from
relatively basic strategies of therapeutic delivery to more sophisticated
approaches.

Each new technology has been accompanied by practical

applications, allowing physicians and scientists to tackle increasingly difficult
biological questions and clinical challenges10.

The polymeric drug depot: the first ADDS
Perhaps the first and most elementary therapeutic delivery system was
that of the polymeric drug depot, a device intended for the gradual and controlled
release of pharmaceuticals. The earliest drug depots, such as the Norplant®
device, consisted of non-biodegradable polymers and aimed at reducing the cost
and complexity of treatment regimens11. Norplant®, a series of silicone capsules
containing the steroid hormone, levonorgestrel, produced highly effective, longterm contraception12.

Although the device achieved notoriety in the United

States as the subject of a number of class action lawsuits, it continues to be
utilized in the developing world, where it has the major advantage of long-term
efficacy without the need for consumable supplies13. Silicone and other non2

degradable polymers were ultimately replaced by materials such as poly(lacticco-glycolic) acid, or PLGA14.

Biodegradable polymers allow for repeated

administration, and their development enabled new clinical applications, such as
monthly dosing of gonadotropins for the treatment of endometriosis, prostate
cancer, and children with precocious puberty15,16.

The most recent depot

technologies have achieved actual “drug targeting”, in the sense that they
release therapeutics at a site of disease, rather than into the systemic circulation.
The most widely publicized and medically significant example is that of the drugeluting stent (DES), a polymer-coated expandable metal tube, which is deployed
within an atherosclerotic artery as a means to maintain blood flow following
angioplasty.

Bare metal stents, used prior to the invention of DES, were

complicated by high rates of in-stent restenosis (ISR), a pathological process in
which vascular smooth muscle cell proliferation, or “neointimal hyperplasia”,
leads to vessel re-occlusion17. DES, which slowly release immunosuppressive or
anti-proliferative agents from their polymer coating, achieve high local
concentrations of drug with minimal side effects and have dramatically reduced
the incidence of ISR18–20.

Mobile drug delivery systems and a focus tumor targeting
While polymeric depots remain the most significant achievement of the
drug delivery field from both a medical and commercial standpoint, even the most
sophisticated examples employ an elementary targeting strategy – i.e. the direct
implantation of drug at its intended site of action. Since many diseases are
disseminated (e.g. metastatic cancer) or inaccessible to implantable depots, the
focus of the drug delivery field has largely turned to mobile targeting systems.
These are capable of carrying therapeutics to diseased sites throughout the
body, where local factors stimulate release10. The vast majority of this work has
dealt with the delivery of inherently toxic agents, such as antimicrobials and
antineoplastics, which are limited in their dosing and efficacy due to narrow
therapeutic indices. In particular, the treatment of cancer has dominated the field
3

of targeted drug delivery for nearly two decades, perhaps because of the obvious
and intuitive appeal of delivering chemotherapeutic drugs to tumor, while sparing
normal tissues21.
As in other cases, the simplest strategies have been explored first,
amongst them the passive leakage of drug carriers into tumor. The landmark
observation that liposomes and other nanoparticles (NPs) accumulate in
neoplastic tissue in excess of proportional blood flow has been termed the
“Enhanced Permeability and Retention (EPR)” effect22. As the name implies,
EPR is believed to be the result of a combination of phenomena. First, NPs that
are normally too large to cross the endothelial barrier are able to permeate
through defective and discontinuous neovasculature, which is formed by rapidly
growing tumors. Second, NPs are poorly cleared from tumor interstitium due to
impaired lymphatic drainage23. The EPR effect has had a profound and lasting
impact on the development of drug targeting systems, despite the fact that it only
applies to treatment of cancer, and specifically, the targeting of solid tumors. In
general, priority has been placed on the development of long-circulating drug
carriers, which maintain the high plasma concentrations needed to drive passive
tumor targeting. Since anti-neoplastic drugs are typically toxic, retention of drug
carrier in the bloodstream has the added benefit of preventing access to normal
tissues (e.g. the bone marrow), thus reducing dose-limiting side effects24.

Lessons from the clinic: liposomes and early polymer conjugates
The most successful drug carriers – from a clinical standpoint – have been
passively targeted liposomal formulations of small molecule chemotherapeutics.
The prime example is that of doxorubicin, a highly effective anticancer drug,
which unfortunately causes cumulative, dose-dependent, and irreversible
cardiomyopathy25. Loading doxorubicin into long-circulating polyethylene glycol
(PEG)-coated liposomes leads to a drastic reduction in its plasma clearance rate
(0.1L/hr vs. 45L/hr for free drug) and volume of distribution (4L as opposed to
254L for free drug), confirming the ability of the drug carrier to limit access to
4

normal tissues26.

The first FDA approved nanoparticle, Doxil® (PEGylated

doxorubicin liposomes) demonstrated significantly less cardiotoxicity in clinical
trials than free doxorubicin27.

At the same time, the EPR-mediated tumor

targeting suggested by early pharmacokinetic studies26, failed to translate into a
marked improvement in clinical efficacy, with overall survival rates similar to
those of free doxorubicin, depending on the type of cancer being treated and
combination of therapies utilized27,28.
The development of another liposomal drug, amphotericin B, is a
remarkably similar story.

Amphotericin is a highly effective anti-fungal agent

whose utility is limited by dose-dependent and often irreversible nephrotoxicity.
Early studies suggested that incorporation of amphotericin into liposomes could
prevent its interaction with mammalian cell membranes29. Moreover, a passive
targeting mechanism was discovered based on non-specific binding of the drug
carrier to the fungal cell wall. Electron microscopy revealed that amphotericinloaded liposomes were disrupted by this interaction and free drug released into
the fungal cytoplasm30.

This exciting pre-clinical work led to industrial

development and clinical testing of AmBisome (liposomal amphotericin B), which
demonstrated significant reductions in nephrotoxicity, as compared to free drug.
As with Doxil®, however, AmBisome has been somewhat of a disappointment in
that the antimicrobial efficacy appears to be similar to free amphotericin31. Given
these relatively modest clinical results, it is not surprising that both therapeutics
have faded from widespread use. AmBisome has been largely eclipsed by the
equally effective and less toxic echinocandin class of antifungals32, and Doxil®
has been in nearly continuous nationwide shortage since going off patent in
2009, with no generic form of the drug available25. In February, 2013, the FDA
approved generic doxorubicin HCl liposomes, but it remains to be seen to what
extent the drug will regain use after this hiatus33.
Liposomal formulations are by no means the only ADDS available for the
delivery of toxic, small molecule drugs.

In fact, liposomes have relatively short

circulation times in comparison to many newer drug carriers, in part because of
5

their limited capacity for PEGylation34.

More stable carriers have been

developed based on N-(2-hydroxypropyl)-methacrylamide (HPMA), polyglutamic
acid (PGA), cyclodextrin, and diblock PEG/PLGA copolymers35. The elucidation
of endocytic pathways in the 1950s and 60s lead to an important realization by
the Nobel laureate Christian De Duve, who suggested that the lysosome might
be a useful target for polymeric drug carriers36. Peptide linkers susceptible to
lysosomal proteases, such as Gly-Phe-Leu-Gly, were used to conjugate drugs to
HPMA, such that the resulting complex would be stable in the circulation, but
susceptible to cleavage once the conjugate had been internalized by
endocytosis24. Other polymers, like PGA, are directly degraded by lysosomal
proteases37, whereas some incorporate pH sensitive bonds to encourage
degradation in the lysosome and release of free drug within the cell38. A few
classes of polymer conjugates have advanced sufficiently to reach clinical trials.
The first, HPMA copolymer-Gly-Phe-Leu-Gly-doxorubicin, or PK1 (FCE28068),
was tested in patients with non-small-cell lung cancer (NSCLC), colon cancer,
and anthracycline-resistant breast cancer. No cardiotoxicity was observed, even
in patients receiving large cumulative doses of doxorubicin, but the drug
produced only partial therapeutic responses, and clinical trials were not
continued39. The most extensive clinical testing to date has been with a PGA
conjugate, paclitaxel poliglumex, or Xyotax. After early trials in NSCLC were
positive, multiple phase III trials were conducted, all of which missed their
primary endpoint of improved survival. Although Xyotax appears to decrease
incidence of paclitaxel-induced side effects, this was not enough to sustain its
clinical development37.

In general, the lesson may be that passive targeting

strategies, while capable of reducing off-target side effects from toxic smallmolecule drugs, are not enough to produce the “magic bullets” envisioned by
Paul Ehrlich and long-expected by the medical community.

6

Ligand-targeted therapeutics
The limited success of liposomal carriers and early polymer conjugates
has turned attention to the development of more sophisticated targeting
strategies. In particular drug carriers have been decorated with nutrients, peptide
hormones, antibodies, and other molecules designed to promote binding and
uptake by target cells. The renewed interest in ligand targeting is not entirely
surprising, given the recent commercial success of monoclonal antibody (mAb)
therapeutics.

One of the most successful examples has been that of folate

targeting. While folic acid is essential for proliferation of all mammalian cells,
only a few cell types, amongst them cancer cells, express high affinity folate
receptors (FRs)40. A variety of potent anti-cancer drugs have been generated by
conjugation of toxic agents to folate.
internalized.

These conjugates bind FRs and are

In some cases, such as the pseudomonas exotoxin PE38, the

cargo has a built-in mechanism of endosomal escape41.

In other cases,

conjugates have been designed with disulfide linkages, resulting in the discharge
of free drug in the reducing environment of the endosome42. Most importantly,
the development of folate-targeted therapeutics has been accompanied by
cognate imaging agents, which allow for the identification and selection of
patients whose tumors overexpress FRs. The pairing of molecular imaging and
targeted drug delivery is a powerful concept, which has led to unprecedented
success and multiple ongoing clinical trials43.

New priorities: the emergence of macromolecular biotherapeutics
Perhaps the most significant shift in the field of drug targeting is the one
currently underway, which has been driven by the rapid growth of a new class of
drugs, macromolecular biotherapeutics.

In the thirty years since the FDA

approval of recombinant human insulin, biotherapeutics (also referred to as
“biologics”) have become a major force in the pharmaceutical industry44. This
rapidly growing category now accounts for 5 of the top 10 best-selling drugs and
more than 50% of the portfolio of most pharmaceutical companies45. The most
7

successful examples have been recombinant proteins that boost natural
protective mechanisms, which are deficient or defunct in human disease.
Examples include erythropoietin (EPO) administered to boost red cell production
in patients with chronic renal failure and granulocyte colony-stimulating factor (GCSF) used to combat chemotherapy-induced neutropenia46. While both EPO
and G-CSF have achieved widespread use and commercial success47, they
represent a relatively small subset of biotherapeutics that require no site-specific
delivery.

Like small molecule drugs, most macromolecules (one notable

exception being mAbs) do not inherently accumulate at their intended site of
therapeutic action. If anything, the size, complexity, and biocompatibility of these
drugs limits their ability to permeate cell membranes and makes them more
susceptible to the body’s mechanisms of inactivation and elimination48.
Moreover, the greatest advantage of biotherapeutics – their extreme specificity
for particular endogenous biological pathways – also represents one of their
greatest challenges, in that these agents require precise delivery to specific
locations in order to exert optimal activity.
A good example is that of small interfering ribonucleic acids (siRNA),
which are, in principle, able to reversibly silence the expression of any gene of
interest. siRNA could become the most important class of therapeutics in history,
with the capacity to modulate the pathogenesis of nearly any disease. However,
they must be delivered to a specific multiprotein complex, the RNA-induced
silencing complex (RISC), in order to have an effect. Numerous obstacles stand
between siRNA and the RISC, including RNAse-mediated destruction, immune
recognition and clearance, lack of tissue targeting, inefficient cellular uptake, and
inability to escape endosomal compartments and reach the perinuclear region of
the cytoplasm49. As a result, most of the RNA therapeutics in early clinical trials
either require direct application of genetic material to the organ of interest (e.g.
intravitreal injection) or target the liver via lipid nanoparticles naturally taken up
through the fenestrated endothelium50.
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Another interesting example is that of fibrinolytic enzymes. Nearly two
decades after the landmark 1995 NINDS trial51, which demonstrated a long-term
benefit of recombinant tissue plasminogen activator (t-PA) in the setting of acute
ischemic stroke, less than 5% of stroke patients receive fibrinolytic therapy52.
The strict eligibility criteria, which exclude the vast majority of patients, are the
result of a narrow therapeutic window and potentially life-threatening toxicity,
intracranial hemorrhage53. As is often the case, poor pharmacokinetics resulting
from extremely rapid clearance (the plasma half-life of free t-PA is approximately
3-1/2 minutes)54 and the presence of a circulating inhibitor55, necessitate large
bolus doses and continuous infusion in order to achieve effective thrombolysis.
This increases the cost and risk of side effects and has severely limited clinical
use. A variety of efforts have been made to alter pharmacokinetics and protect
the drug en route to its therapeutic site, including PEGylation of the enzyme,
genetic modification, and encapsulation in a variety of liposomal and polymeric
drug carriers34. While these modifications have improved circulation time, many
simultaneously

impede

clot

permeation

and

accessibility

to

fibrin.

Correspondingly, none of these approaches have proven to have a decisive
advantage over t-PA in the treatment of acute stroke56.
The general lesson appears to be that targeting of macromolecular
biotherapeutics may be quite different from the delivery of inherently toxic, small
molecule drugs, especially in applications unrelated to cancer. Characteristics
which may be ideal for an ADDS carrying doxorubicin or paclitaxel, such as
prolonged circulation time and impaired entry into normal tissues, may be
disadvantageous in the delivery of biotherapeutics.

Attachment to targeting

ligands, polymers, or stealth agents (e.g. PEG) may impair access to the
necessary site of action or block partnering with cofactors. Until technology is
developed to precisely localize biotherapeutics and optimize their interaction with
endogenous partners, the clinical development of numerous candidate drugs will
be stifled, and the translation of many scientific discoveries will remain
impossible.
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II. Developing Therapeutics for Acute Vascular Disorders
The obstacles encountered in the development and clinical testing of
recombinant fibrinolytics demonstrate the enormous challenges which face the
scientific and medical community in designing therapeutics for the treatment of
acute vascular disorders. Cardiovascular disease is already the most common
cause of death in industrialized nations, and its incidence is on the rise57.

The

acute manifestations are typically unforeseeable and life-threatening, meaning
that candidate therapeutics must work after the onset of symptoms, achieve rapid
efficacy, and demonstrate limited off-target side effects.

The most severe

vascular disorders, including sepsis, acute lung injury, and post-traumatic multiorgan failure, have been labeled “critical illnesses”, owing to the lack of diseasespecific therapies and reliance on sophisticated supportive measures in treating
afflicted patients58.

Despite substantial improvements in emergency and

intensive care, the morbidity and mortality of these conditions has remained
essentially unchanged59,60.

Endothelial cells: a critical target
The vascular endothelium, once thought to be a passive barrier between
blood and tissue, is now recognized to have an important role in many of these
same diseases in which the medical field has struggled to achieve improved
outcomes61–63. Endothelial cells (ECs) project a variety of protein complexes into
the vascular lumen, which interact with circulating blood components and allow
ECs to sense and respond to changes in flow, coagulation, nutrient delivery, and
inflammation64,65.

In the last several decades, scientists have elucidated a

variety of endothelial mechanisms, which help to maintain blood fluidity, control
vascular tone and permeability, and regulate the innate immune response66.
Advances in tissue culture have allowed the study of these mechanisms not only
at rest, but under different patterns of flow67. Molecular biology has enabled the
identification of many of the proteins involved in these protective pathways, as
well as variations in their level of expression in segments of the vasculature
10

exposed to high or low shear stress. Finally, the creation of endothelial-specific
genetic modifications in animals and the identification of disease-linked
polymorphisms in patients have provided insight into the relative importance of
these endothelial pathways in human disease68–70.
Despite the enormous accumulation of knowledge regarding endothelial
biology, physicians and scientists remain largely unable to influence the
endothelial mechanisms known to play a part in acute vascular disorders in
humans. Only a small number of drugs have significant effects on ECs and
those that do typically have little endothelial specificity (e.g. non-steroidal antiinflammatory

drugs),

require

complex

regimens

of

administration

(e.g.

epoprostenol)71, or are meant for the treatment of chronic conditions like
systemic

hypertension

(e.g.

angiotensin

converting

enzyme-inhibitors).

Biotherapeutics, in particular, tend to have no innate affinity for the endothelium,
and only a tiny fraction of administered dose is typically retained at the vascular
margin.

While the field of drug targeting has begun to take an interest in

endothelial delivery, efforts have focused on directing therapeutics to tumorassociated neovasculature72.

Only a small number of investigators have

prioritized the delivery of biotherapeutics to normal ECs, and limited capacity
exists to target specific vascular beds or areas of endothelial activation73–76.

The Protein C pathway and its role in acute vascular disease
Amongst

the

endogenous

endothelial

systems

considered

for

pharmacologic intervention, the protein C pathway has attracted perhaps the
most intense interest, in part because of its involvement in the coagulation
cascade, the innate immune response, and the control of vascular permeability77.
The existence of protein C (PC) was first predicted in 1970 by Ewa Marciniak,
who described a “coagulation inhibitor elicited by thrombin”78. In 1976, this factor
was identified as vitamin K dependent and named “protein C” by Johan Stenflo,
because it was present in the third major peak eluted off of an anion exchange
column following the barium citrate adsorption of bovine plasma79. Like other
11

vitamin K-activated, gamma-carboxyglutamate (Gla) containing factors, PC was
found to be a zymogen, cleavable by thrombin and Russell’s viper venom80.
Unlike other coagulation zymogens, however, the majority of PC could be
recovered in serum81. Indeed, its slow rate of activation in clotting assays led
Charles Esmon to search for an endothelial cofactor capable of accelerating the
generation of activated protein C (APC).

By perfusing discarded pig’s ears

(collected from a local slaughterhouse) with thrombin and PC, Esmon discovered
that such a cofactor was present, and subsequent efforts led to the isolation of
thrombomodulin (TM)82.
TM was ultimately characterized as an endothelial transmembrane
glycoprotein capable of altering the enzymatic specificity of thrombin. When
bound to TM, thrombin no longer activates fibrinogen, Factor V, or platelets, but
instead generates APC83. Although it is often thought of as an anticoagulant, TM
differs substantially from molecules like antithrombin, heparin, hirudin, and the
new direct thrombin inhibitors (e.g. dabigatran). Rather than simply inhibiting
thrombin activity, TM couples it to the generation of APC, which has antiinflammatory, anti-apoptotic, and endothelial barrier stabilizing activity, in addition
to anticoagulant functions.

The importance of the protein C pathway is

demonstrated by the uniform lethality of homozygous protein C deficiency, which
manifests as neonatal purpura fulminans84.

No genetic form of human TM

deficiency exists, presumably due to embryonic lethality.

In fact, even mice

homozygous for a single point mutation in TM, which disrupts thrombin binding,
have a severe prothrombotic and hyperinflammatory phenotype85.
The role of the protein C pathway in maintaining homeostasis is also
demonstrated, albeit in less absolute terms, by the nearly universal finding of
endothelial TM deficiency in the presence of human vascular disease. Loss of
TM has been demonstrated in nearly every condition involving acute or chronic
vascular

inflammation,

from

sepsis

and

atherosclerosis and diabetic neuropathy86–89.

ischemia/reperfusion

injury

to

In addition to transcriptional

downregulation, there is evidence to suggest that TM is internalized, inactivated,
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and cleaved from the endothelial membrane in these conditions. A wide variety
of mediators have been implicated, including cytokines, reactive oxygen species,
and neutrophil-derived proteases90–93. Given its pervasive nature, it seems likely
that this process must have conferred a selective advantage in some
evolutionary situations, such as localized infection or trauma. In the context of
contemporary human medicine, however, loss of endothelial TM is no longer
advantageous and has become an important component of the pathogenesis of
numerous vascular diseases.
In addition to TM and PC, a third molecule, the endothelial protein C
receptor (EPCR), has a critical role in the protective functions of this system.
APC generation by the TM/thrombin complex is accelerated between 5 and 20
fold when PC is bound to EPCR, depending on whether measurements are
made in vitro or in vivo94,95. Moreover, EPCR appears to play a central role in
mediating the anti-inflammatory, anti-apoptotic, and barrier stabilizing effects of
APC84. Although EPCR has a short cytoplasmic tail and no direct intracellular
signaling activity, it co-localizes with the protease-activated receptor 1 (PAR1) in
caveolin-1 rich microdomains and participates in its activation by APC96.
Specifically, APC must be bound to EPCR to cleave PAR197. Some in vitro
experiments indicate a second mechanism of protective signaling through PAR1,
in which the specificity of thrombin is altered when EPCR is occupied by PC,
switching it from a pro-inflammatory to anti-inflammatory signal98.

The

APC/EPCR complex also appears to signal through additional receptors,
including the sphingosine-1-phosphate receptor (S1PR) and PAR399–101. Like
TM, EPCR is cleaved from the endothelial membrane in the presence of
systemic inflammation. Plasma levels of a soluble form of EPCR (sEPCR) are
elevated in human sepsis and a variety of autoimmune disorders and correlate
with the severity of underlying disease102–104.

In vitro studies indicate that a

matrix metalloprotease is responsible for EPCR cleavage and that release of
sEPCR is stimulated by inflammatory mediators, reactive oxygen species, and
coagulation factors105.
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Studies with genetically modified mice have confirmed the role of EPCR in
mediating protective effects of the protein C pathway in vivo. These results are
particularly significant because of the distinct tissue distribution of TM and EPCR,
the former predominantly found on capillaries and smaller vessels and the latter
with higher expression on large vessels106.

These differing patterns of

expression have led to questions about the importance of EPCR and its
partnering with TM in vivo. Nonetheless, EPCR is clearly involved in mediating
protective effects, based on observations that mice with genetically-induced
EPCR deficiency (~10% of normal expression levels) are more susceptible to
endotoxemia than wild type controls, whereas animals with endothelial-specific
overexpression of EPCR (150 times normal expression levels) are markedly
more resistant69,107. One theory is that the level of colocalization of TM, EPCR,
and PAR1 might vary depending on the vascular bed examined, and that this
might explain the overall importance of this signaling pathway, despite distinct
patterns of expression noted in some organs84. Consistent with this idea, one
recent study investigated the importance of EPCR in maintaining endothelial
barrier function in various organs and found significant variation depending on
the vascular bed involved108. Figure 1.1 shows the major components of the
Protein C Pathway, in schematic form, and their primary functions at the luminal
endothelial cell membrane.

III. Biotherapeutic Interventions into the Protein C Pathway
Multiple approaches have been proposed to reverse the pathogenic
suppression of the protein C pathway, including endothelial gene therapy and the
infusion of recombinant proteins. The former approach has intuitive appeal and
has provided proof-of-principle for replenishing endothelial TM109–111, and
potentially EPCR as well. Nonetheless, it requires the site-specific delivery of
siRNA or other genetic material – not only to endothelial cells, but a specific
compartment of the EC cytoplasm. As alluded to above, significant technological
limitations exist which make gene therapy unrealistic, except in rare clinical
14

contexts (e.g. ex vivo viral transduction of ECs in harvested vein segments prior
to bypass grafting)112. Even if the technical limitations are overlooked, temporal
considerations are unlikely to permit this approach in the treatment of emergent
conditions like sepsis, stroke, and acute lung injury.

Xigris® and other recombinant proteins
In 1987, Taylor and Esmon reported that recombinant human APC (rhAPC)
protected baboons from an otherwise lethal infusion of bacteria113. The timing of
this discovery was fortuitous, coinciding not only with the emergence of
biotherapeutics as a viable class of pharmaceuticals, but also the recognition of
systemic

inflammation

and

derangements

in

coagulation

as

important

components of human sepsis114. rhAPC was developed by the pharmaceutical
industry and became one of a number of recombinant proteins tested in septic
patients in the late 1990s.

Ultimately, the phase III PROWESS trial

demonstrated a survival benefit in patients randomized to rhAPC (28-day
mortality of 24.7% vs. 30.8% with placebo), and led to the FDA approval of
drotrecogin alfa (rhAPC), or Xigris®115.

Unfortunately, as in the case of

recombinant t-PA, poor pharmacokinetics severely limited its clinical utility. In
fact, the similarities to t-PA are striking: rhAPC is rapidly cleared (the plasma
half-life of free APC is approximately 13 minutes)116 and inactivated by a
circulating inhibitor, and these factors led to the decision to administer the drug
via continuous infusion.

This in turn increased the cost and risk of life-

threatening hemorrhage, and ultimately, the drug was withdrawn from the market
when its risks were shown to outweigh any potential benefit117.
A variety of efforts have been made to replicate the beneficial
effects seen with rhAPC, while avoiding its negative characteristics. Genetically
modified forms have been created which demonstrate reduced inactivation of
Factors Va and VIIIa118.

These mutants lack the anti-coagulant and pro-

fibrinolytic effects of wild type APC, while preserving other beneficial activities. In
fact, the lack of anti-coagulant effect actually results in indirect anti-inflammatory
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Figure 1.1. The Protein C Pathway
Protein C bound to EPCR is activated at the endothelial membrane by the
thrombin-TM
TM complex. Resultant APC may remain bound to endothelial EPCR,
activating PAR-1
1 and other receptors, or it may exert a vvariety
ariety of other effects,
amongst them inhibition of the coagulation cascade (via Protein S-dependent
S
cleavage of Factors Va and VIIIa) and modulation of immune cell (neutrophil,
(ne
macrophage, and dendritic cell
cell) functions.
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actions not seen with rhAPC, due to the increased generation of thrombin and
activation of the thrombin-activatable fibrinolysis inhibitor (TAFI). In addition to
blocking the efficient activation of plasmin, TAFI inhibits bradykinin and the
anaphylatoxins C3a and C5a119, both of which contribute to the systemic
inflammatory response. Although these genetic modifications may address some
of the limitations of rhAPC120, the modified drugs still face significant
pharmacokinetic challenges and their ability to succeed in the clinical realm has
yet to be determined.
Another strategy for augmenting the protein C pathway is the infusion of
soluble forms of TM. Unlike infusion of an activated zymogen, soluble TM (sTM)
reproduces some of the “on demand” nature of the endogenous protein C
pathway, generating a biological effect primarily at sites of thrombin
generation121. Genetic modifications have been made to sTM to separate the
function of its domains, prolong circulation time, and prevent inactivation by
reactive oxidant species93,122,123. While preliminary studies in animal models and
early stage human clinical trials have demonstrated beneficial effects124–126, sTM
and its derivatives fail to reproduce a key aspect of the protein C pathway, its
localization to the endothelial membrane. Although improper localization in this
case may not be as significant as it is with siRNA or other biotherapeutics, it does
prevent the interaction of recombinant TM with a key cofactor, the endothelial
protein C receptor (EPCR).

Endothelial targeted biotherapeutics
Endothelial targeting of recombinant TM was first reported by our
laboratory in 2008127.

To anchor sTM to the luminal membrane, its natural

location and (presumably) site of optimal activity, it was fused to a PECAM-1specific single chain antibody fragment, 390 scFv.

The 390 scFv/TM fusion

protein was found to bind to immobilized PECAM-1 in vitro and to lung ECs
following IV injection. Mice treated with 390 scFv/TM were protected from both
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ischemic and inflammatory lung injury, without the bleeding side effects seen with
equipotent doses of recombinant mouse APC127.
While the ability of endothelial-anchored 390 scFv/TM to partner with
endogenous EPCR was not tested in these initial experiments, studies conducted
in the field of biomaterials suggested that this would be an important question.
Material scientists have long taken an interest in the protein C pathway as a
potential means of preventing the activation of the immune system and
coagulation cascade on implantable medical devices128.

TM has been

immobilized on polyurethane, PEG-modified glass, and even liposomes129–131. In
2006, one group reported in vitro flow studies utilizing a membrane-mimetic
material, which had been functionalized with phospholipids and TM. The rate of
APC generation was measured following the perfusion of thrombin and PC. At
relatively low TM surface density, increases in TM surface content accelerated
APC production. Beyond a certain critical TM density, however, a plateau was
reached and further increases in TM surface content had no effect132.

This

finding was attributed to a limitation in protein C availability at the surface,
presumably due to the absence of EPCR. Subsequent efforts achieved higher
rates of APC generation via co-immobilization of TM and EPCR, but the effect
was only seen if the recombinant proteins were in close proximity (< 10nm).
Random, unordered distribution of TM and EPCR was not effective133.

This

potentially stringent requirement for proximity between TM and EPCR gave rise
to several important questions regarding the potential partnering of EC-anchored
390 scFv/TM and endogenous EPCR.

IV. Scope of the Dissertation
As indicated above, the primary goal of targeting recombinant TM to the
endothelial membrane has been to optimize its activity by allowing for partnering
with endogenous cofactors. As of 2009, it remained unknown to what extent 390
scFv/TM was able to take advantage of its localization.
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There were three

questions, in particular, which we wanted to answer, and which form the basis of
this dissertation:

1) Is thrombin bound to membrane-anchored scFv/TM capable of interacting
with PC bound to EPCR?

There were two reasons for concern that partnering between scFv/TM and
EPCR might not be possible. The first was related to the design of the 390
scFv/TM fusion protein, which was constructed with the scFv moiety on the Nterminal end and the sTM moiety on the C-terminal end (figure 1.2a). While this
design was chosen for technical reasons (prior data suggested that 390 scFv
may not bind to PECAM-1 if a large cargo protein like TM was fused to its Nterminus), it left the sTM moiety in an “inverted” conformation. The N-terminal
lectin domain of TM is typically the most distal to the membrane, with the six
EGF-like domains, including the thrombin-binding site (EGF-like domains 5 and
6), more proximal. In contrast, the lectin domain in the fusion is adjacent to the
scFv and the EGF domains may be further from the membrane, depending on
the exact conformation the protein takes after binding to PECAM-1 (figure 1.2b).
The second, and somewhat related, reason for concern was that the
combination of the scFv moiety and PECAM-1 might introduce too much distance
between recombinant TM and the surface membrane to allow access to PC and
EPCR (Figure 1.2b). Some separation from the plasmalemma is known to be
required for full activity of the thrombin/TM complex, which sits approximately
65Å from the cell surface134.

Specifically, this was studied in a series of

experiments, in which the Ser/Thr rich region of TM (which is positioned
immediately adjacent to the membrane) was replaced by polypeptides of varying
length. Decreasing the size of this spacer progressively diminished thrombin
binding and protein C activation, suggesting that the active site is optimally held
at a certain distance from the membrane135. Nonetheless, the interposition of
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Figure 1.2. Schematic depiction of 390 scFv/TM molecular design and
positioning vs. endogenous TM
(a) sTM moiety was placed on 3’, or C
C-terminal, end. (b) The “inverted”
conformation of the sTM moiety, its distance from the plasmalemma, and its
localization to cell-cell
cell junct
junctions
ions could all impair partnering with endogenous
EPCR.
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PECAM-1 and the 390 scFv might introduce a significantly greater distance than
65Å, and the effect of this displacement on partnering with EPCR was unknown.

2) Assuming the thrombin-scFv/TM complex is physically capable of interacting
with PC-EPCR, do differences in the distribution of PECAM-1 and EPCR
along the EC membrane prevent effective enzymatic partnering?
PECAM-1 on ECs is predominantly localized to cell-cell junctions136,137, whereas
endogenous TM and EPCR are believed to be concentrated in lipid rafts in the
endothelial apical plasmalemma96,138.

Based the results of the previously

described experiments involving co-immobilization of TM and EPCR on artificial
surfaces, there was concern that PECAM-anchored TM might have insufficient
proximity to allow effective partnering with EPCR (figure 1.2b).
Chapter 2 details our experimental approach to these first two questions.
We describe an assay for measuring the activation of PC by cell membranebound TM fusion proteins. We use this method to show that 390 scFv/TM is
capable of partnering with EPCR, at least while anchored to the membrane of
non-endothelial cells, engineered to overexpress mouse PECAM-1 and EPCR.
In contrast, experiments on mouse ECs indicate that PECAM-anchored 390
scFv/TM is largely unable to partner with EPCR, at least in comparison to
endogenous TM.

3) What approaches can be designed to allow or improve enzymatic partnering
between

EC-anchored

scFv/TM

and

EPCR

(without

compromising

therapeutic delivery)?

In the light of the results presented in Chapter 2, two strategies were developed
for enhancing enzymatic partnering between endothelial-targeted TM and EPCR.
The implementation and validation of these approaches are discussed at length
in Chapters 3 and 4.
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CHAPTER TWO: PECAM-BOUND scFv/TM – MEASUREMENT OF
PROTEIN C ACTIVATION AND PARTERING WITH EPCR

I. INTRODUCTION
As discussed in Chapter 1, vascular immunotargeting of drugs involves
conjugation or recombinant fusion to specific affinity ligands of determinants on
the luminal surface of ECs. Although in the past it has been thought of as a
strategy for controlling and altering pharmacokinetics, its application to
biotherapeutics is primarily intended to precisely localize drugs and allow optimal
interaction with endogenous partners. Indeed, the primary justification for
targeting recombinant TM to ECs, reported by our lab in 2008, was not one of
pharmacokinetics127. Other means exist for achieving prolonged circulation of
sTM, including subcutaneous injection, chemical modification (e.g. PEGylation),
genetic alteration (e.g. solulin), and attachment to blood cells139–141. While these
therapeutics are systemic and cannot be directed to one organ in particular, the
fact that sTM activates PC only at sites of thrombin generation “localizes” its
effect to sites of inflammation or thrombosis.
Given that endothelial targeting of TM was primarily motivated by potential
partnering with EPCR and other endogenous cofactors, our group had great
interest in determining if such interaction was possible. To address these
questions, we developed an assay for measuring the activation of protein C by
cell-bound 390 scFv/TM and utilized this method to determine the extent of
partnering with EPCR.
II. RESULTS
Studies on Non-Endothelial REN Cells
The human mesothelioma cell line REN is a useful model system, with no
expression of mouse PECAM, ICAM, TM, or EPCR at baseline. REN-PECAM
22

Figure 2.1. Non-endothelial REN cell system
Western blot demonstrating expression of mouse endothelial proteins on REN
cells (wt = wild type) and stably transfected REN-PECAM cells, with MS1 mouse
endothelial cells included for comparison.
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cells, which stably express mouse PECAM-1, have been utilized in our laboratory
extensively (Figure 2.1)142,143.
Binding and functional activity of 390 scFv/TM on PECAM-expressing REN cells
Both 390 scFv and 390 scFv/TM fusion protein demonstrated nanomolar affinity
to REN-PECAM cells. Little or no non-specific binding was seen to wild type
REN cells (Figure 2.2a,b). For the next series of experiments, we developed an
assay for measuring the activation of protein C by TM fusion proteins bound to
the surface of REN cells.

390 scFv/TM demonstrated dose-dependent,

thrombin-mediated activation of protein C on REN-PECAM cells, but not on wild
type REN cells (Figure 2.3).

Recombinant sTM was used as an additional

control and showed no activity on either cell type.

EPCR expression potentiates the functional activity of 390 scFv/TM bound to
REN-PECAM cells
Having determined the baseline rate of protein C activation by REN cellbound 390 scFv/TM, we next assessed its ability to partner with EPCR in the
membrane. To achieve this, EPCR expression was induced on REN-PECAM
cells, producing the stable cell line REN-PECAM-EPCR. Expression of EPCR
was confirmed by western blotting (Figure 2.4). Expression of EPCR expression
resulted in ~4-fold enhancement of thrombin-mediated APC generation by 390
scFv/TM (Figure 2.5a). To confirm that this effect was dependent on EPCR, we
utilized a monoclonal antibody that blocks the binding of PC to murine EPCR and
thereby inhibits its ability to accelerate APC production by the thrombin-TM
complex69. Treatment with this antibody resulted in approximately 75% reduction
in APC generation (Figure 2.5b).

Studies on Mouse Endothelial Cells
EPCR expression on MS1 cells vs. REN-PECAM-EPCR cells
While transfected REN cells are convenient for studying TM fusion
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Figure 2.2. Binding of 390 scFv and scFv/TM to REN-PECAM cells
Cell based ELISAs show binding of (a) 390 scFv and (b) 390 scFv/TM fusion
protein to PECAM expressing REN cells. No significant binding is seen to wild
type REN cells. Experiments were done in triplicate (each point shown
represents three wells). SD are shown but too small to be seen in most cases.
EC50 is shown for each curve.
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Figure 2.3. APC generation by 390 scFv/TM on REN-PECAM cells
390 scFv/TM activates protein C while bound to PECAM-expressing cells.
Minimal APC is generated on wild type REN cells, presumably due to lack of
binding. All experiments were done in triplicate. Data shown are mean ± SD.
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Figure 2.4. Creation of REN cells stably expressing PECAM and EPCR
Western blot of REN-PECAM-EPCR cells, which stably overexpress mouse
EPCR. REN wt, REN-PECAM, and MS1 endothelial cells included as
comparison.
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Figure 2.5. APC generation by 390 scFv/TM on REN-PECAM-EPCR vs.
REN-PECAM cells
(a) A ~4-fold increase in APC generation is seen when 390 scFv/TM is anchored
to REN-PECAM-EPCR cells, as compared to EPCR-negative counterparts.
Differences between groups were highly significant (p < 0.001) at all (non-zero)
doses of 390 scFv/TM fusion protein. (b) Cells treated with anti-EPCR mAb1560,
which blocks protein C binding to EPCR, show ~75% reduction in APC
generation. Differences between groups were highly significant (p < 0.001) at all
(non-zero) doses of fusion protein. All experiments were done in triplicate. Data
shown are mean ± SD, error bars too small to be seen at some points.
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proteins, they clearly represent an artificial system, in which the surface
expression and distribution of PECAM, ICAM, and EPCR do not necessarily
reflect what is present on endothelial cells. For example, radioimmunoassays
performed using 125I-labeled anti-EPCR revealed that the number of binding sites
on REN-PECAM-EPCR cells is an order of magnitude higher than on MS1
mouse endothelial cells (Figure 2.6).

Binding of 390 scFv/TM to MS1 endothelial cells
390 scFv/TM demonstrated specific binding to PECAM-1, as evidenced by
near complete inhibition of binding by a 10-fold excess of parental 390 mAb
(Figure 2.7). Calculated affinity constants were similar to those seen in previous
experiments using REN-PECAM cells.

Suppression of endogenous TM on MS1 cells
Measuring the activity of 390 scFv/TM while bound to MS1 cells proved to
be substantially more complicated than on REN cells, due to high level of
expression of endogenous TM. These cells express endogenous TM at high

level in a stable fashion resistant to agents that typically suppress its level in
endothelium (e.g., TNF and other cytokines).

To measure fusion protein-

specific APC generation on endothelial cells, we experimented with several
methods of suppressing the activity of endogenous TM.
methods utilized mouse TM-specific siRNA.

The first of these

Although western blotting

demonstrated robust suppression of TM levels, relatively high levels of lipid
transfecting reagent were required (Figure 2.8a). The cells were damaged in this
process and inevitably lifted off gelatinized 24 well plates during the repeated
washes of the APC generation assay. We subsequently transfected MS1 cells
with a TM-specific shRNA vector containing the puromycin resistance gene.
Stably

transfected

cells

were

selected

and

maintained

in

puromycin.

Unfortunately, western blotting demonstrated no difference in the expression of
mouse TM in shRNA-transfected vs. wild type cells (Figure 2.8b).
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Figure 2.6. Quantification of EPCR on ECs vs. REN-PECAM-EPCR cells
(a) Radioimmunoassays of 125I-labeled anti-EPCR antibody (mAb1560).
(b) Summary of anti-EPCR binding parameters on each cell type.
Radioimmunoassays were done in quadruplicate (i.e. each data point represents
4 wells of cells). Data shown are mean ± SD.
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Figure 2.7. Binding of 390 scFv/TM to MS1 mouse ECs
Specificity is demonstrated by inhibition of binding by 10-fold excess of parental
390 mAb. All experiments were done in triplicate (i.e. each data point represents
3 wells of cells). Data shown are mean ± SD, error bars too small to be seen at
some points.
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Figure 2.8. Attempts to knockdown endogenous TM on MS1 cells
(a) Mouse TM specific siRNA effectively suppressed TM, especially at high
doses. Unfortunately, cell toxicity made APC generation assays technically
impossible. (b) Stable transfection of a mouse TM specific shRNA did not result
in effective knockdown, despite antibiotic selection.
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Isolation of lung microvascular endothelial cells from TMpro/pro mice
TMpro/pro mice are homozygous for a single amino acid mutation,
Glu404Pro, in the interdomain loop between the fourth and fifth EGF-like
domains of TM.

This mutation results in a 75% reduction in the level of

expression of TM in lung homogenates, a ~100-fold reduction in thrombin
binding, and a ~1000-fold reduction in the rate of APC generation144.

We

reasoned that TMpro/pro ECs would provide an ideal system for testing activation of
protein C by EC-bound 390 scFv/TM. Accordingly, lung endothelial cells were
isolated from TMpro/pro mice. The cells were grown to passage 4 (Figure 2.9a)
and tested for the binding of 390 scFv/TM. Unfortunately, no binding was seen
on TMpro/pro ECs, in contrast to MS1 cells (Figure 2.9b).

Blockade of endogenous TM on MS1 cells
Another strategy employed to suppress the activity of endogenous TM
was that of antibody blockade. A variety of anti-mouse TM (mTM) antibodies
were screened for their ability to block thrombin binding and APC generation,
with PPACK-inactivated thrombin used as a positive control. While several antimTM mAbs had no effect, a polyclonal anti-mTM antibody was able to fully inhibit
APC generation (Figure 2.10a). Unlike PPACK-thrombin, the polyclonal antibody
had a sustained effect after washing (Figure 2.10b). Sustained blockade of 6070% of endogenous TM activity, provided by anti-TM antibody, enabled
measurement of dose responsive, 390 scFv/TM-dependent protein C activation
(Figure 2.10c).

Functional activity of EC-bound 390 scFv/TM and lack of EPCR partnering
We employed anti-mTM antibody blockade to assess protein C activation
by 390 scFv/TM anchored to MS1 cells. Since the expression of PECAM-1 on
ECs is more than an order of magnitude higher than that of TM (106 copies/cell
vs. 4x104 copies/cell)145,146, we expected that saturating concentrations of 390
scFv/TM (e.g. 40nM based on enzyme-linked Immunosorbent assays, ELISAs)
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Figure 2.9. Isolation and culture of lung ECs from TMpro/pro mice
(a) Phase contrast image of isolated ECs. (b) Cell-based ELISA demonstrated
binding of 390 scFv/TM to MS1 cells, but not isolated TMpro/pro cells.
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Figure 2.10. APC generation on MS1 cells following blockade of
endogenous TM
(a) Blockade of endogenous TM with PPACK-inactivated thrombin and polyclonal
anti-TM prevents thrombin-dependent APC generation. Monoclonal anti-TM
antibodies, clone 411 and clone 273 (generously provided by Dr. Stephen J.
Kennel, University of Tennessee, Knoxville, TN) did not inhibit APC generation.
(b) Antibody blockade, but not inactivated IIa, had a sustained blocking effect
when cells were washed prior to addition of thrombin and protein C. (c) Antibody
blockade of endogenous TM enabled measurement of dose responsive, fusion
protein-dependent protein C activation. All experiments were done in triplicate.
Data shown are mean ± SD, error bars too small to be seen at some points.
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Figure 2.11. APC generation by 390 scFv/TM on MS1 cells
MS1 cells blocked with anti-mTM antibody and treated with 390 scFv/TM
unexpectedly showed less activation of PC than unblocked MS1 cells (which
reflect the activity of endogenous TM). One potential explanation is the finding
that APC generation by 390 scFv/TM is not significantly affected by blockade of
EPCR (p = 0.32), unlike unblocked MS1 cells (p << 0.001), indicating ineffective
partnering of the fusion protein with this key co-factor. Experiments were done in
triplicate (i.e. n=3). Data shown are mean ± SD.
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would result in substantially higher levels of APC than unblocked MS1 cells.
When we compared unblocked MS1 cells to antibody-blocked cells treated with
40nM of 390 scFv/TM, however, we found that the latter actually generated
significantly less APC (Figure 2.11).
To assess the role of EPCR in this result, we utilized EPCR blocking
antibody and found that treatment of MS1 cells with the anti-EPCR antibody
resulted in approximately 50% reduction in thrombin-dependent activation of
protein C by endogenous TM. In contrast, there was no significant effect on the
activation of protein C by 390 scFv/TM (Figure 2.11).

III. CONCLUSIONS

Several significant conclusions can be drawn from the in vitro data
presented in this chapter. First, experiments using the non-endothelial REN
cell system clearly demonstrate that partnering between TM fusion proteins
and EPCR is at least possible. In this system, in which EPCR is marked
overexpressed (~10-fold more copies per REN-PECAM-EPCR cell than MS1
cell), PECAM-anchored 390 scFv/TM is able bind thrombin and access PC
bound to EPCR.

This is conclusively demonstrated by both the 4-fold

increase in APC generation seen on REN-PECAM-EPCR cells, as well as the
near complete reversal of this effect following EPCR blockade with mAb1560.
This antibody has been well characterized and is known to inhibit approximately
70% of protein C binding to mouse EPCR, eliminating to substantial extent, but
not completely, its ability to accelerate the activation of protein C69. Our results

were quite consistent with these figures, demonstrating a 75% reduction in
390 scFv/TM-dependent APC generation following antibody blockade (Figure
2.5b).
The other main finding is the apparent inability of PECAM-bound 390
scFv/TM to partner with EPCR on MS1 cells.

Two pieces of evidence

suggest that 390 scFv/TM differs substantially from endogenous TM in terms
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of its partnering with endogenous co-factors. First, anti-mTM blocked MS1
cells treated with a saturating concentration of 390 scFv/TM generate only
~70% as much APC than unblocked MS1 cells (Figure 2.11). Since PECAM1 is typically expressed at much higher levels per EC than TM (~20 fold
difference has been reported for HUVECs), this observation indicates a huge
difference in the amount of APC generated per TM molecule.

Since 390

scFv/TM and sTM demonstrate similar rates of APC generation in fluid-phase
assays127, there was no reason to suspect a difference in thrombin binding or
catalytic efficiency. Instead, we suspected that our data might be explained
by a difference in partnering with EPCR. Indeed, blockade of EPCR using
mAb1560 had essentially no effect on APC generation by 390 scFv/TM, whereas
a highly significant 50% reduction was seen on unblocked MS1 cells (Figure
2.11).

Together, these data strongly suggest that PECAM-anchored 390

scFv/TM is unable to effectively partner with endogenous EPCR, at least with
respect to protein C activation.

IV. MATERIALS AND METHODS
Cell lines and animals
MS1 cells were purchased from ATCC (Manassas, VA) and maintained in
DMEM with 10% FBS and 1X antibiotic-antimycotic (Life technologies, Grand
Island, NY). TMpro/pro mice were a generous gift from Dr. Helmut Weiler at the
Blood Center of Wisconsin.

Antibodies and other reagents
Purified anti-PECAM (390) antibody was obtained from BioLegend (San
Diego, CA). Anti-mTM polyclonal antibody (AF3894) and anti-EPCR polyclonal
antibody (AF2749) were purchased from R&D systems (Minneapolis, MN). AntiEPCR blocking antibody, mAb1560, was supplied by the Esmon laboratory.
Collagenase A and HRP-conjugated Anti-FLAG (M2-HRP) antibody were
obtained from Sigma Aldrich (St Louis, MO). PPACK-inactivated thrombin was a
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generous gift of Sriram Krishnaswamy. Bovine thrombin was purchased from
Sigma.

Human protein C zymogen was obtained from Haematologic

Technologies (Essex Junction, VT). APC substrate S-2366 was purchased from
Diapharma (West Chester, OH). Mouse TM-specific siRNA (sc-36687), control
siRNA

(sc-37007),

siRNA

transfection

reagent

(sc-29528),

and

siRNA

transfection media (sc-36868) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). FITC-conjugated Anti-ICAM-2 antibody, clone 3C4, was from
Southern Biotech (Birmingham, AL).

Generation of REN-PECAM-EPCR stable cell line
A vector containing the entire coding sequence of mouse EPCR and a
portion of the 5’ and 3’ UTRs (nt 171-1413) was obtained from the Esmon
laboratory147. The EPCR cDNA was excised using XbaI and EcoRI and ligated
into the pcDNA3.1/Zeo(-) vector (Life Technologies, Grand Island, NY). Since
REN-PECAM cells already stably express the Geneticin resistance gene, this
expression vector (which confers resistance to the antibiotic Zeocin) was utilized.
Cells were transfected with Lipofectamine 2000 and REN-PECAM-EPCR cells
were selected in media with Geneticin and 250 µg/mL of Zeocin.

Live cell ELISA Assays
ELISAs were performed on live cells as previously described142, although
in the experiments reported here, cell monolayers were incubated with increasing
concentrations of scFv or scFv/TM fusion protein rather than whole antibodies.
Since all fusion proteins carry a C-terminal triple FLAG tag, anti-FLAG (M2)peroxidase (HRP) conjugate was used as a detection antibody. In experiments
involving MS1 endothelial cells, specific binding of 390 scFv/TM was assessed
by co-incubation with 10-fold excess of parental 390 mAb. ELISA binding data
was analyzed and binding parameters (EC50) were determined using PRISM 6.0
software (GraphPad, San Diego, CA)142.
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Protein C Activation Assays
Generation of APC by scFv/TM fusion was assayed following the
incubation of confluent REN cell or MS1 monolayers with 390 scFv/TM fusion
protein. Cells were washed x 3 with media to remove non-specifically bound
protein, prior to the addition of 1 nM thrombin and 100 nM protein C. In all cases,
protein C activation occurred at 37°C in assay buff er (20 mM Tris, 100 mM NaCl,
1 mM CaCl2, 0.1% (w/v) bovine serum albumin (BSA), pH 7.5) and the reaction
was stopped by addition of an excess of hirudin. In experiments involving MS1
cells, the monolayer was first treated with 200nM anti-mTM antibody to block
endogenous TM and then washed x 3 prior to incubation with scFv/TM fusion
protein.

In experiments involving EPCR blockade, cells were incubated with

300nM of anti-EPCR antibody (Ab1560) for 15 minutes prior to the addition of
protein C and thrombin. This antibody has been well characterized and is known
to inhibit approximately 70% of protein C binding, eliminating to a substantial
extent the ability of EPCR to accelerate the activation of protein C by the
thrombin-TM complex69.
Radioimmunoassays (RIAs) using 125I-labeled Antibodies
Anti-EPCR antibody (mAb1560) was directly radioiodinated with [125I]NaI
(Perkin Elmer, Waltham, MA) and purified using Zeba desalting spin columns
(ThermoScientific). Radiolabeling efficiency was > 75% and free iodine was <
5%, post-purification. RIAs were performed and binding parameters (Kd, Bmax)
determined as previously reported142.

siRNA knockdown of mouse TM
MS1 cells were transfected with a pool of three mouse TM-specific siRNA
or control siRNA per manufacturer protocol. Specific siRNA sequences were not
made available by the manufacturer. Cells were plated and allowed to grow until
they were approximately 75% confluent. 10 pmol of siRNA were mixed with
transfection reagent and allowed to sit for 30 minutes at room temperature prior
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to addition to each well of cells. Cells were exposed for 7 hours, after which they
were gently washed and incubated with antibiotic-free growth media. 48 hours
later, cells were lysed for analysis of TM expression by western blot.

shRNA knockdown of mouse TM
MS1 cells were transfected with a pool of three mouse TM-specific
shRNAs using Lipofectamine 2000 (as with siRNA, sequences proprietary to
manufacturer). Cells were selected using 4 µg/mL puromycin, a concentration
found to kill 100% of wild type MS1 cells.
Isolation of TMpro/pro lung endothelial cells
Animal studies were carried out in accordance with the Guide for the Care
and Use of Laboratory Animals as adopted by the NIH, under protocols (803320
and 804349) approved by University of Pennsylvania IACUC. The genotype of
TMpro/pro mice was verified using genomic DNA obtained from mouse tail tips.
Lung endothelial cells were isolated as previously described148. Briefly, neonatal
pups (7-14 days old) were anaesthetized with ketamine and xylazine and given
an intramuscular injection of 25 µL of heparin (1000U/mL). The thoracic cavity
was entered and 5 mL of ice cold DMEM was injected into the pulmonary
circulation via the right ventricle.

1 mL of collagenase A (1.0 mg/mL) was

instilled through the trachea into the lungs, which were then tied off. The lungs
were removed and incubated with 5 mL of collagenase A for 30 min at 37°C. 30
mL of sterile PBS was added and the tube was shaken. The resulting tissue/cell
suspension was passed through a 70µm filter, centrifuged, resuspended in
complete DMEM, and plated onto gelatinized T75 flasks. The cells were grown
in M199 medium for 2 days, trypsinized, and subjected to FACS sorting using
anti-ICAM-2 antibody (clone 3C4). The sorted cells were pooled, plated at 3x105
cells/mL in a T25 flask, and split 1:2 at each passage.
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Data analysis and statistics
Results are expressed as mean ± SD unless otherwise noted. Significant
differences between means were determined using Student’s t-test or one-way
ANOVA followed by appropriate multiple comparison (Tukey) test.

For

experiments involving the comparison of multiple dose response curves (e.g.
APC generation by 390 scFv/TM on REN-PECAM vs. REN-PECAM-EPCR cells),
two-way ANOVAs were performed.

P<0.05 was considered statistically

significant.
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CHAPTER THREE: OPTIMIZATION OF PARTNERING WITH ENDOGENOUS
EPCR

I. INTRODUCTION
Having reached the conclusion that 390 scFv/TM anchored to PECAM on
ECs likely does not partner efficiently with endogenous EPCR, our attention
turned to potential strategies for enhancing interaction between endothelial
targeted TM and this key co-factor. Another cell adhesion molecule, ICAM-1,
has been shown to localize to apical membrane microdomains on ECs, and to
cluster in lipid rafts following cytokine stimulation, leukocyte adhesion, and/or
binding of anti-ICAM-1 antibodies149. Since EPCR, PAR1, and to some extent,
TM, are also believed to localize to these membrane microdomains96, we
hypothesized that anchoring TM to ICAM-1 might allow for enhanced proximity
and improved partnering with endogenous co-factors and signaling pathways.

II. RESULTS
PECAM-1 vs. ICAM-1
Relative proximity of PECAM-1 and ICAM-1 to EPCR
To assess the relative proximity of EPCR to PECAM-1 and ICAM-1,
mouse MS1 endothelial cells were stained for each antigen and imaged using a
fluorescence microscope (Figure 3.1a). 390 mAb, the parental antibody of the
390 scFv/TM fusion, was used to stain PECAM-1. YN1/1.7.4 (hereafter referred
to as YN1) was used to stain ICAM-1. This mAb has been extensively studied in
our laboratory and blocks leukocyte LFA-1 interaction150.

In agreement with

previous reports, most PECAM-1 staining occurred at cell-cell borders136, with
minimal overlap with EPCR. In contrast, there was overlap of staining for ICAM1 and that for EPCR (Figure 3.1a).

Binding of anti-ICAM and anti-PECAM mAbs to MS1 cells
Next, we studied the binding to MS1 cells of 125I-labeled YN1 and 390
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Figure 3.1. Localization of PECAM-1, ICAM-1, and EPCR on mouse
endothelial cells
(a) Immunofluorescence images demonstrate superior co-localization of ICAM-1
and EPCR, as compared to PECAM-1 and EPCR. (b) Radioimmunoassay data
using 125I-labeled anti-PECAM (390 mAb) and anti-ICAM (YN1 mAb) to
determine affinity and number of binding sites per endothelial cell.
Radioimmunoassays done in quadruplicate (i.e. each point represents four wells
of cells), data shown are mean ± SD, some error bars too small to be seen.

44

mAbs. The antibodies had similar subnanomolar affinities (Kd of approx. 0.12
and 0.22nM, respectively), although PECAM-1 provided ~20-fold more binding
sites than ICAM-1 (approximately 240,000/cell vs. 12,000/cell, respectively),
reflecting a substantial difference in the level of cell surface expression of these
molecules (Figure 3.1b).

Interestingly, according to these data, MS1 have a

slightly lower number of anti-PECAM binding sites than human umbilical vein
endothelial cells (HUVECs, ~106 binding sites per cell145), which may reflect
innate differences between these cell lines. MS1s are a transformed cell line,
whereas HUVECs are primary ECs. Moreover, MS1s are smaller than HUVEC,
so their number of PECAM copies per cell surface area may be fairly similar.

Construction of an ICAM-targeted scFv/TM Fusion Protein
Cloning of YN1 scFv and fusion to sTM
Using a previously reported PCR-based technique, we next cloned an
anti-ICAM-1 scFv from the YN1 hybridoma151. Whereas cloning of the VH cDNA
was straightforward, the typical approach produced only the previously reported
Y3-Ag 1.2.3 myeloma VL sequence152 (i.e. the myeloma used to make the YN1
hybridoma). As a result, mass spectrometry was used to identify an 8 amino acid
peptide unique to the ICAM-specific VL, which was then used to produce a full
length VL cDNA (Figure 3.2). The VH and VL cDNAs were assembled into a
complete anti-ICAM-1 YN1 scFv, which was fused to the extracellular domain of
TM. The YN1 scFv/TM construct was designed to be identical to 390 scFv/TM,
with the scFv moiety on the 5’ end (Figure 3.3a). The purity of YN1 scFv and
YN1 scFv/TM is shown by gel electrophoresis (Figure 3.3b).

Functional activity of 390 scFv/TM, YN1 scFv/TM, and sTM in solution
To ensure that activity of the TM moiety in YN1 scFv/TM was intact, we
measured APC generation in a fluid-phase assay. Both YN1 scFv/TM and 390
scFv/TM fusion proteins were nearly identical to soluble TM in their ability to
stimulate thrombin-mediated activation of protein C (Figure 3.4).
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Figure 3.2. Cloning of anti-ICAM VH and VL cDNAs
(a) A PCR-based approach to cloning of variable heavy and light chain regions
(VH and VL) utilizes degenerate 5’ primers corresponding to the beginning of the
1st framework region (FR1) and a 3’ primer corresponding to the start of the
constant region151. (b) In the case of the YN1 hybridoma, the VH domain was
readily cloned, but the typical approach amplified only the myeloma-derived VL,
which is nearly identical to the anti-ICAM VL at the N-terminus of FR1. Mass
spectrometry was used to identify an 8 amino acid sequence unique to the antiICAM VL. This sequence allowed the majority of the VL to be cloned. A 9 amino
acid sequence in FR4 was paired with the original 5’ primers to identify the
residues at the N-terminus of the anti-ICAM VL.
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Figure 3.3. Design and synthesis of YN1 scFv and scFv/TM
(a) Assembly of VH and VL sequences into scFv and scFv/TM constructs. (b)
SDS PAGE gel electrophoresis of YN1 scFv, soluble TM, and YN1 scFv/TM
fusion protein under reducing and non-reducing conditions.
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Figure 3.4. Fluid-phase APC generation
Thrombin-dependent activation of protein C was measured in solution and
compared to soluble TM (sTM). The proteins were mixed with 0.5 nM thrombin
and a large excess of protein C (1 µM). The reaction was stopped after 15min by
addition of hirudin. The fusion proteins performed identically to sTM over a range
of concentrations.
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Creation of ICAM-1 expressing REN cells
As discussed in Chapter 2, the human mesothelioma cell line REN is a
useful model system, with no expression of mouse PECAM, ICAM, TM, or EPCR
at baseline (see Figure 2.1). Although wild type REN cells do express low levels
of human ICAM-1153, they were found to have no detectable cross-reactivity with
YN1 mAb by flow cytometry and cell-based ELISA (data not shown). As a result,
we created a new stably transfected cell line, REN-mICAM cells, which express
high levels of mouse ICAM-1.

Binding and functional activity of YN1 scFv/TM on ICAM-expressing REN cells
Both YN1 scFv and YN1 scFv/TM demonstrated nanomolar affinity to
REN-ICAM cells, with no non-specific binding seen on wild type REN cells
(Figure 3.5a,b).

YN1 scFv/TM demonstrated dose-dependent, thrombin-

mediated activation of protein C on REN-ICAM cells, but not on wild type REN
cells (Figure 3.6a). Recombinant sTM showed no activity on either cell type.

EPCR expression potentiates the functional activity of YN1 scFv/TM on RENICAM cells
We next assessed the ability of ICAM-anchored YN1 scFv/TM to partner
with EPCR in the artificial REN cell system. As had been done for REN-PECAM
cells, EPCR expression was induced on REN-ICAM cells, producing the stable
cell line REN-ICAM-EPCR. As was seen with 390 scFv/TM, EPCR expression
resulted in ~4-fold enhancement of thrombin-mediated APC generation by YN1
scFv/TM (Figure 3.6b). In summary, while bound to their corresponding anchors
on non-endothelial REN cells, PECAM and ICAM-targeted scFv/TM fusion
proteins demonstrated roughly equivalent functional activity and similar capacity
to partner with cellular EPCR, at least with respect to thrombin-dependent APC
generation.
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Figure 3.5. Binding of YN1 scFv and scFv/TM to REN-ICAM cells
Cell based ELISAs show binding of (a) YN1 scFv and (b) YN1 scFv/TM fusion
protein to ICAM expressing REN cells. No significant binding is seen to wild type
REN cells. Experiments were done in triplicate (i.e. each point shown represents
three wells of cells). Data shown are mean ± SD, although error bars are too
small to be seen in most cases. EC50 is shown for each curve.
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Figure 3.6. APC generation by YN1 scFv/TM on REN-ICAM cells with and
without EPCR expression
(a) YN1 scFv/TM activates protein C while bound to ICAM-expressing cells.
Minimal APC is generated on wild type REN cells, presumably due to lack of
binding. (b) A ~4-fold increase in APC generation is seen when YN1 scFv/TM is
anchored to REN-ICAM-EPCR cells, as compared to EPCR-negative
counterparts. Differences between groups were highly significant (p < 0.001) at
all (non-zero) doses of YN1 scFv/TM fusion protein. All experiments were done in
triplicate (i.e. each point shown represents three wells of cells). Data shown are
mean ± SD, although error bars are too small to be seen in some cases.
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Studies on Mouse Endothelial Cells
Binding of YN1 scFv/TM to quiescent and TNF-stimulated endothelial cells
The binding of YN1 scFv/TM was tested on MS1 cells.

Unlike most

endothelial cells (e.g., HUVEC), quiescent MS1 cells express significant levels of
ICAM-1, although they demonstrate a similar ~1.5-fold increase in response to
TNF or other cytokine stimulation. YN1 scFv/TM demonstrated ICAM-specific
binding to MS1 cells, as evidenced by near complete inhibition of binding by a
10-fold excess of parental antibody (Figure 3.7). Likewise, stimulation of the
cells with mouse TNF demonstrated a small but significant increase in fusion
protein binding. Calculated affinity constants were similar to those seen in RENICAM cell experiments.

Functional activity of EC-bound 390 scFv/TM and lack of EPCR partnering
We employed anti-mTM antibody blockade (described in Chapter 2) to
assess protein C activation by YN1 scFv/TM anchored to MS1 cells.

APC

generation was compared to unblocked MS1 cells and antibody blocked MS1
cells treated with 40nM 390 scFv/TM. As with 390 scFv/TM, a high concentration
of YN1 scFv/TM was used (40nM), in order to saturate available binding sites.
The maximum numbers of PECAM- and ICAM-binding sites were known from
our radioimmunoassays (Figure 3.1b). Despite a 20-fold difference in binding
sites, only a ~1.5 fold difference was seen in the level of APC generation (Figure
3.8a). We assessed the role of EPCR using the mAb1560 blocking antibody and
found that YN1 scFv/TM-treated MS1 cells showed a 50% reduction in protein C
activation, similar to unblocked MS1s and in contrast to 390 scFv/TM-treated
cells (Figure 3.8a).
In order to directly compare the activity of EC-bound YN1 scFv/TM and
390 scFv/TM, APC generation was normalized to the number of binding sites per
cell. This analysis revealed that YN1 scFv/TM has ~15-fold greater functional
activity then 390 scFv/TM, while anchored to MS1 cells (Figure 3.8b).
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Figure 3.7. Binding of YN1 scFv/TM to quiescent and activated MS1 cells
Specificity is demonstrated by inhibition of binding by 10-fold excess of parental
390 mAb. All experiments were done in triplicate (i.e. each point shown
represents three wells of cells). Data shown are mean ± SD, although error bars
are too small to be seen in some cases.
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Figure 3.8. APC generation by PECAM- vs. ICAM-anchored scFv/TM on
antibody blocked MS1 cells
(a) Despite a 20-fold difference in the number of PECAM vs. ICAM binding sites,
antibody-blocked MS1 cells treated with 390 scFv/TM generate only ~1.5-fold
more APC than those treated with YN1 scFv/TM. Moreover, APC generation by
YN1 scFv/TM, but not 390 scFv/TM, is affected by blockade of EPCR (p <
0.001). The 50% reduction is similar to what is seen with unblocked MS1 cells
(reflecting the activity of endogenous TM). (b) Normalization of APC generation
to number of binding sites shows that functional activity of YN1 scFv/TM is ~15fold greater than 390 scFv/TM (p << 0.001). Experiments done in triplicate. Data
shown are mean ± SD.
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Figure 3.9. YN1 scFv/TM reduces MIP-2 in a mouse model of lung injury
(a) Timeline of intratracheal LPS lung injury model. In experiments assessing
endothelial barrier dysfunction, a tracer amount of 125I-labeled albumin was
injected 5 minutes prior to LPS administration. (b) Concentration of the critical
neutrophil chemokine, MIP-2, in bronchoalveolar lavage (BAL) fluid. Data shown
are mean ± SD, with number of animals as shown.
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Figure 3.10. YN1 scFv/TM reduces inflammatory marker expression and
endothelial barrier dysfunction in mouse lung injury model
(a) mRNA transcript levels of pro-inflammatory cell adhesion molecules, VCAM-1
and E-selectin, in lung homogenate. (b) Endothelial barrier dysfunction, as
measured by leakage of 125I-labeled albumin from blood into lung interstitium
and/or alveolar space. All data shown are mean ± SD, with number of animals
as shown.
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In vivo Experiments
Endothelial protective effects of YN1 scFv/TM and 390 scFv/TM in a mouse
model of acute lung injury
Anti-inflammatory effects of YN1 scFv/TM and 390 scFv/TM were then
compared in a model of lung inflammation, in which mice receive an intratracheal
(IT) injection of endotoxin154. The fusion proteins, or PBS vehicle, were injected
intravenously 30 minutes prior to LPS challenge (Figure 3.9a). Relevant indices
of lung inflammation and injury were measured, including the level of MIP-2 in
bronchoalveolar lavage fluid (Figure 3.9b), expression of cell adhesion molecules
VCAM-1 and E-selectin in lung tissue homogenate (Figure 3.10a), and
extravascular leakage of radiolabeled albumin injected intravenously and
detected in the lungs (Figure 3.10b). While both YN1 scFv/TM and 390 scFv/TM
showed evidence of protection, the ICAM-targeted fusion protein was more
effective in all cases.

III. CONCLUSIONS

The data presented in this chapter support the notion that the ability of
endothelial targeted scFv/TM fusion proteins to interact with endogenous
EPCR depends on which surface determinant is targeted, and that this
variable may have significant therapeutic implications, with YN1 scFv/TM
fusion demonstrating more potent protective effects in vivo. Our data, along
with prior reports regarding the distribution of ICAM and PECAM on the
endothelial membrane136,137,149, suggest that the proximity of the TM fusion to
EPCR may be the critical factor. Figure 3.11 shows a simplified model of an
endothelial cell with the TM fusion proteins bound to their target ligands. The
figure accurately depicts the fusion proteins binding the domains of PECAM-1
and ICAM-1 which lie furthest from the plasma membrane, consistent with the
location of their target epitopes142,150. The schematic highlights the proposed
difference in proximity to the EPCR/Protein C complex, which may account for
our experimental observations.
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Figure 3.11. Schematic representation of TM fusion proteins anchored to
the endothelial plasmalemma
The proximity of ICAM
ICAM-targeted
targeted scFv/TM to endogenous EPCR/Protein C may
account for its enhanced activity in vitro and in vivo.
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It is worth noting that these results align with the general notion that
anchoring agents to distinct determinants on the same target cell may produce
distinct outcomes, due to the differing functions, location, surface density, and
trafficking of these surface molecules. For example, our laboratory previously
reported that binding of the H2O2-producing enzyme, glucose oxidase (GOX), to
endothelial cells induced varying degrees of vascular damage, depending on
whether PECAM or TM was chosen as the surface target155. The variation in
outcome in those experiments was attributed to the substantially different
function of these two surface molecules and the consequences of their blockade
by GOX conjugates. In contrast, it is difficult to attribute the current results to any
functional difference between ICAM and PECAM, two closely related proteins
which both support leukocyte adhesion, pro-inflammatory signaling, and uptake
of antibody conjugates via a similar endocytic mechanism156,157. For this reason,
we believe that the most logical explanation for our current experimental results
is the distinct localization of ICAM and PECAM on the endothelial membrane and
their differing capacity to allow interaction of anchored scFv/TM with EPCR.
In summary, our first approach for enhancing partnering of endothelialtargeted TM and EPCR involved the rational selection of an endothelial
determinant, ICAM-1, based on knowledge of its membrane distribution. We
constructed and synthesized a recombinant ICAM-targeted scFv/TM fusion
protein. In comparing its function to that of PECAM-targeted scFv/TM, we found
evidence of superior functional activity on ECs, partnering with endogenous
EPCR, and enhanced protective effects in a mouse model of lung injury.
Together, these results suggest that delivery of recombinant TM to the
endothelial membrane in a way that mimics its natural distribution and optimizes
interaction with endogenous co-factors is more effective.

These findings

underscore the complexity of targeting biotherapeutics to the plasmalemma, and
suggest that precision on a nanometer scale is necessary for optimal
biotherapeutic effect.
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IV. MATERIALS AND METHODS
Cell lines
YN1 hybridoma and MS1 cells were purchased from ATCC (Manassas,
VA). YN1 cells were cultured in RPMI 1640 supplemented with 10% (v/v) fetal
bovine serum (FBS). MS1 cells were maintained in DMEM with 10% FBS and
1X antibiotic-antimycotic (Life technologies, Grand Island, NY).

Antibodies and other reagents
Purified anti-PECAM (390) and anti-ICAM (YN1) antibodies were obtained
from BioLegend (San Diego, CA). Anti-TM polyclonal antibody (AF3894) and
anti-EPCR polyclonal antibody (AF2749) were purchased from R&D systems
(Minneapolis, MN). Anti-EPCR blocking antibody, mAb1560, was supplied by the
Esmon laboratory. HRP-conjugated Anti-FLAG (M2-HRP) antibody was obtained
from Sigma Aldrich (St Louis, MO). Alexa Fluor-labeled secondary antibodies
were purchased from Life Technologies (Grand Island, NY). Bovine thrombin,
LPS (serotype B4), and mouse TNF were purchased from Sigma.

Human

protein C zymogen was obtained from Haematologic Technologies (Essex
Junction, VT). APC substrate S-2366 was purchased from Diapharma (West
Chester, OH).

Endothelial cell immunofluorescence staining
MS1 cell monolayers were grown in 8 well µ-slides (Ibidi, Verona, WI) and
fixed for 20 minutes at room temperature (RT) with Histochoice (Amresco, Solon,
OH). In some cases, cells were treated with 10 ng/mL mouse TNF for 8 hours
prior to fixation. After three washes, cells were blocked with 3% (w/v) BSA in
HBSS for 1 hour at RT. Cells were stained with either anti-PECAM (390, 15
µg/mL) or anti-ICAM (YN1, 1 µg/mL) mAbs, in addition to polyclonal goat antimouse EPCR (0.5 µg/mL) for 2 hours at RT. Cells were washed three times with
0.1% Tween in HBSS and then stained with Alexa Fluor 594 anti-rat (1:200) and
Alexa Fluor 488 anti-goat (1:1000). After 1 hour incubation, cells were washed
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four times with 0.1% Tween in HBSS and once in PBS. ProLong Gold Antifade
reagent with DAPI (Life technologies, Grand Island, NY), and a coverslip was
applied and cells were allowed to dry overnight prior to immunofluorescence
imaging.

Cloning of anti-ICAM VL and VH cDNAs
Total cellular RNA was isolated from YN1 hybridoma cells using the
RNeasy kit (Qiagen, Valencia, CA). Combined reverse transcription and PCR
was performed using SuperScript One Step RT-PCR kit (Life Technologies,
Grand Island, NY) and previously reported FR1 region primers151.

Mass

spectrometry to identify an 8-aa sequence unique to the ICAM-specific VL was
done by the Core Facility at the University of Pennsylvania using purified YN1
antibody that had been run on a denaturing SDS PAGE gel and excised.
Degenerate PCR primers were synthesized based on this sequence and used to
produce a full length VL distinct from the known Y3-Ag 1.2.3 myeloma VL
sequence152.

Assembly and expression of anti-ICAM scFv and anti-ICAM scFv/TM constructs
Completed anti-ICAM VL and VH cDNAs were assembled into constructs
encoding anti-ICAM scFv and the anti-ICAM scFv/TM fusion protein. In each
case, VH and VL sequences were separated by a (GGGGS)3 linker, and a triple
FLAG tag was appended to the 3’ end (C terminus) for purposes of purification
and detection.

The YN1 scFv moiety was separated from the extracellular

domain of TM (amino acids Leu17-Ser517) by an (SSSSG)2AAA linker. Both
proteins were expressed in S2 cells and purified using a C-terminal triple FLAG
tag. Purity was assessed using SDS-PAGE.

Generation of REN-derived Stable Cell Lines
REN-mICAM cells. A full-length cDNA for mouse ICAM-1 was purchased
from Thermo Scientific (Rockford, IL). The clone was sequenced and found to
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contain the entire coding sequence of mouse ICAM-1 and a portion of the 5' and
3' UTRs (nt 46-2440) between EcoRI and XbaI restriction enzyme sites. The
clone was excised and ligated into the pcDNA3 mammalian expression vector,
and transfected into REN cells using Lipofectamine 2000 (Life Technologies,
Grand Island, NY). Stably expressing cells were selected in media containing
200 µg/mL of Geneticin (Life Technologies, Grand Island, NY).

REN-mICAM-mEPCR cells. A vector containing the entire coding
sequence of mouse EPCR and a portion of the 5’ and 3’ UTRs (nt 171-1413) was
obtained from the Esmon laboratory147. The EPCR cDNA was excised using
XbaI and EcoRI and ligated into the pcDNA3.1/Zeo(-) vector (Life Technologies,
Grand Island, NY). Since REN-ICAM cells already stably express the Geneticin
resistance gene, this expression vector (which confers resistance to the antibiotic
Zeocin) was utilized. Cells were transfected with Lipofectamine 2000 and RENICAM-EPCR cells were selected in media with Geneticin and 250 µg/mL of
Zeocin.

Live Cell ELISA Assays
Enzyme-linked Immunosorbent Assays (ELISAs) were performed on live
cells as described in Chapter 2. ELISA binding data was analyzed and binding
parameters (EC50) were determined using PRISM 6.0 software (GraphPad, San
Diego, CA)142.
RIAs using 125I-labeled antibodies
390 and YN1 mAbs were directly radioiodinated with [125I]NaI (Perkin
Elmer, Waltham, MA) and purified using Zeba desalting spin columns
(ThermoScientific). In all cases, radiolabeling efficiency was > 75% and free
iodine was < 5%, post-purification. RIAs were performed and binding parameters
(Kd, Bmax) determined as previously reported142.
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Protein C activation assays
Generation of APC by cell-bound scFv/TM fusion was assayed as
described in Chapter 2. For fluid-phase APC generation experiments, sTM, 390
scFv/TM, and YN1 scFv/TM were each mixed with 0.5nM thrombin and 1 µM
protein C in a micro-Eppendorf tube. In all cases, protein C activation occurred
at 37°C in assay buffer (20 mM Tris, 100 mM NaCl, 1 mM CaCl2, 0.1% (w/v)
BSA, pH 7.5) and the reaction was stopped by addition of an excess of hirudin.
As described in Chapter 2, MS1 cell monolayers were first treated with anti-TM
antibody to block endogenous TM and then washed x 3 prior to incubation with
scFv/TM fusion protein. The amount of APC generated by cell-bound fusions in
these experiments was normalized to the number of binding sites per cell, as
determined in MS1 RIAs (approximately 240,000/cell for PECAM-1 and
12,000/cell for ICAM-1).

Antibody blockade of EPCR was performed as

described in Chapter 2, using 300nM of anti-EPCR antibody (Ab1560) for 15
minutes prior to the addition of protein C and thrombin.

IT LPS model
Animal studies were carried out in accordance with the Guide for the Care
and Use of Laboratory Animals as adopted by the NIH, under protocols (803320
and 804349) approved by University of Pennsylvania IACUC. C57BL/6 male
mice weighing 20-30 gm were anaesthetized and placed in a supine position.
Acute lung injury was induced via IT injection of 2 mg/kg of endotoxin in a volume
of 100 µL of PBS. Endotoxin injection was followed immediately by injection of
150 µL of air, to ensure even distribution of LPS throughout all distal airspaces.
In relevant experiments, anti-PECAM scFv/TM, anti-ICAM scFv/TM, or PBS
vehicle and

125

I-labeled albumin were injected intravenously prior to LPS

administration as shown.

6 hours after induction of lung injury, blood was

withdrawn from the inferior vena cava and animals were euthanized.
In experiments involving tracing of

125

I-labeled albumin, a catheter was

placed in the pulmonary artery and the pulmonary circulation was gently flushed
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with PBS prior to the harvesting of organs. The amount of radioactivity in the
blood and lungs was measured using a Wizard2 2470 gamma counter
(PerkinElmer, Waltham, MA). The localization ratio of

125

I-albumin (calculated as

(% injected dose present in lung/g of lung tissue)/blood level) was used as a
surrogate for pulmonary edema.
In other experiments, bronchoalveolar lavage was performed via a 19gauge stainless steel catheter (Harvard Apparatus, Holliston, MA) placed in the
trachea and secured via a 5-0 silk suture. Each animal was lavaged twice with
0.8 mL of ice-cold PBS. The lavages were pooled and MIP-2 was quantified
using a Quantikine ELISA kit (R&D systems, Minneapolis, MN).

For

quantification of VCAM-1 and E-selectin mRNA, lungs were homogenized with
steel beads (Sigma) and a Tissue Lyser II (Qiagen). Total RNA was isolated with
RNeasy kit and cDNA was synthesized using the Transcriptor 1st Strand cDNA
Synthesis Kit (Roche Applied Science, Indianapolis, IN). qPCR was performed
using the FastStart DNA MasterPLUS kit (SYBR green) and a Lightcycler 1.5
carousel-based system (Roche Applied Science). Validated Quantitect primers
for mouse VCAM-1, E-selectin, and actin (housekeeping control) were utilized
(Qiagen, Valencia, CA).

Data analysis and statistics
Results are expressed as mean ± SD unless otherwise noted. Significant
differences between means were determined using Student’s t-test or one-way
ANOVA followed by appropriate multiple comparison (Tukey) test.

For

experiments involving the comparison of multiple dose response curves (e.g.
APC generation by YN1 scFv/TM on REN-ICAM vs. REN-ICAM-EPCR cells),
two-way ANOVAs were performed.

P<0.05 was considered statistically

significant.
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CHAPTER FOUR: DUAL TARGETING OF TM AND EPCR FUSION PROTEINS
TO THE ENDOTHELIUM

I. INTRODUCTION
Although anchoring TM to ICAM-1 appears to improve partnering with
endogenous EPCR, PECAM-1 has desirable features from the standpoint of
vascular immunotargeting48. Its constitutive, stable, and high level of expression
throughout the vasculature makes it the preferred choice for targeting of
prophylactic

agents,

e.g.,

prior

to

a

predictable

vascular

insult

like

cardiopulmonary bypass or organ transplantation. Likewise, PECAM-1 differs
from other pan-endothelial determinants (e.g., angiotensin converting enzyme, or
ACE), in that it is relatively poorly internalized by ECs, allowing for surface
targeting of TM fusion proteins. Finally, anchoring of scFv/TM to PECAM-1 is
unlikely to be deleterious, and if anything, would be expected to have an antiinflammatory effect due to inhibition of transendothelial leukocyte migration158,159.
As a result, we wanted to explore the possibility of utilizing PECAM-1 as a
surface determinant for dual targeting of recombinant scFv/TM and scFv/EPCR.
By anchoring both proteins to PECAM-1, we hypothesized that we would achieve
sufficient proximity to allow enzymatic partnering. Another reason for choosing
PECAM-1 as the surface determinant was our discovery of the “collaborative
enhancement” phenomenon, in which paired antibodies to adjacent, distinct
epitopes on PECAM-1 increase each other’s binding to the endothelium in vitro
and in vivo142. Based on this mechanism, we hypothesized that scFv/TM and
scFv/EPCR fusion proteins directed to paired PECAM-1 epitopes would enhance
– rather than competitively inhibit – each other’s binding. Altogether, dual
targeting of these therapeutic fusion proteins would have the capacity to
accelerate protein C activation via two distinct mechanisms: 1. collaborative
enhancement of binding and 2. enzymatic partnering of the TM and EPCR
moieties.
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II. RESULTS
Construction of a PECAM-targeted scFv/EPCR Fusion Protein
Cloning of Mec13 scFv and fusion to mouse EPCR
Previous studies in our laboratory demonstrated that mAbs 390 and
Mec13.3 (hereafter referred to as Mec13), which bind to distinct, but adjacent,
epitopes located in the extracellular Ig-domain 2 of mouse PECAM-1160, enhance
each others binding (Figure 4.1a).

This phenomenon of “collaborative

enhancement” exists in both transfected (i.e. REN-PECAM) cells and mouse
endothelial cells (Figure 4.1b) and also contributes to enhanced endothelial
binding of antibodies in vivo (Figure 4.1c)142.
To take advantage of collaborative enhancement with 390 scFv/TM, we
wanted to design the scFv/EPCR fusion protein using an antibody fragment
derived from the Mec13 hybridoma. As in the cloning of the YN1 scFv described
in Chapter 3, the Mec13 VH cDNA was easily identified using degenerate
framework region 1 (FR1) primers.

Once again, however, this approach

produced only a non-functional, myeloma-derived VL cDNA, with an in frame stop
codon in the FR1 region (Figure 4.2a). As a result, the Mec13 light chain was
sequenced using the N-terminal Edman technique. The first 7 amino acids of the
FR1 region were identified and used to clone of a full length VL cDNA (Figure
4.2a). The VH and VL cDNAs were assembled into a complete anti-PECAM-1
Mec13 scFv, which was fused to the extracellular domain of EPCR. The scFv
moiety was positioned on the 3’ end, to keep the protein C binding site of EPCR
(located on the N-terminal end) freely accessible (Figure 4.2b). Recombinant
soluble mouse EPCR (sEPCR) was synthesized as well. The purity of each
protein is shown by gel electrophoresis (Figure 4.2c).

Binding of Mec13 scFv/EPCR to REN-PECAM cells and immobilized Protein C
Both Mec13 scFv and the Mec13 scFv/EPCR bound to REN-PECAM-
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Figure 4.1. Collaborative enhancement of mAb binding to PECAM-1
(a) Amino acid location of epitopes for mAbs 390 and MEC13 on Ig-domain 2
(IgD2) of mouse PECAM-1 (b) Collaborative binding studies of mAbs 390 and
MEC13 on REN-PECAM cells. Whereas unlabeled self-paired mAb 390 and
mAb MEC13 competitively inhibit binding of [125I]-mAb390 and [125I]-mAb MEC13
to REN-PECAM cells, mAb pairs [125I]-mAb 390/MEC13.3 and [125I]-mAb
MEC13.3/390 enhance binding by 1.5 fold and 2.7 fold, respectively. (c) In vivo
endothelial targeting of [125I]-mAb to PECAM-1 is enhanced by paired antiPECAM-1 mAb. Lung:blood ratio for [125I]-mAb 390/mAb MEC13 and [125I]-mAb
MEC13.3/mAb 390 pairs increases 3.4 fold. The dotted red line is the lung:blood
ratio of [125I]-IgG at 30 minutes. Data is reported as the standard error of the
mean of n = 4–5 animals (***, P = 0.001). (All data reproduced from Chacko A-M
et al. PLoS One 2012, reference 142)
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Figure 4.2. Cloning, assembly, and purification of Mec13 scFv, sEPCR,
and Mec13 scFv/EPCR fusion protein
(a) The Mec13 VL and the myeloma-derived VL are nearly identical at the Nterminus of FR1 region. N-terminal (Edman) sequencing was used to identify a
one amino acid difference (Gln vs. Val), which ultimately enabled amplification of
a full length Mec VL cDNA. (b) Assembly of VH and VL sequences into Mec13
scFv and Mec13 scFv/EPCR constructs. An sEPCR construct was also made
(c) Purity of recombinant proteins as shown by SDS PAGE.
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Figure 4.3. Function of scFv and EPCR moieties of Mec13 scFv/EPCR
fusion protein
(a) Cell based ELISAs show that binding of Mec13 scFv/EPCR fusion protein to
PECAM expressing REN cells is similar to that of Mec13 scFv. No significant
binding is seen to wild type REN cells. (b) Mec13 scFv/EPCR fusion protein
binds immobilized protein C in nearly identical manner as sEPCR. Empty
triangles () indicate non-specific binding of Mec13 scFv/EPCR to BSA-coated
wells. All experiments were done in triplicate (each point shown represents three
wells), with SD shown.
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cells, but not wild type REN cells (Figure 4.3a). Having confirmed the function of
the scFv moiety, the function of the EPCR moiety was tested by comparing the
binding of Mec13 scFv/EPCR and sEPCR to immobilized protein C.

Both

proteins showed equal binding, with no non-specific binding to albumin-coated
wells (Figure 4.3b).

Functional Activity of Mec13 scFv/EPCR
Creation of TM expressing REN wt and REN-PECAM cells
To assess the ability of Mec13 scFv/EPCR to augment protein C
activation by TM/thrombin complex on the cell surface, we generated a series of
transfected REN cells stably expressing mouse TM and/or PECAM-1 on their
surface.

Thrombin-dependent protein C activation was measured on REN-

PECAM-TM cells, which stably express both mouse PECAM-1 and TM (Figure
4.4a), and compared to APC generation on REN-TM and REN-PECAM cells. As
expected, REN-TM and REN-PECAM-TM cells, but not TM-lacking cells (REN
and REN-PECAM) exerted thrombin dependent activation of protein C (Figure
4.4b).

Mec13 scFv/EPCR enhances APC generation on REN-PECAM-TM cells
Mec13 scFv/EPCR stimulated thrombin-dependent production of APC by
REN-PECAM-TM, but not REN-TM cells (Figure 4.4c). This indicates that the
EPCR fusion protein is able to partner with TM in the cell membrane while bound
to PECAM. No such effect was seen with Mec13 scFv or sEPCR (Figure 4.4d),
confirming the need for both functional moieties in the fusion protein to bind to
target cells and partner with TM in the plasma membrane.

Dual Targeting of Mec13 scFv/EPCR and 390 scFv/TM to REN Cells
Mec13 scFv/EPCR and 390 scFv/TM demonstrate collaborative enhancement
Collaborative enhancement of binding was originally described with paired
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Figure 4.4. Functional activity of Mec13 scFv/EPCR fusion protein
(a) Western blotting confirms expression of mouse TM on REN-PECAM-TM and
REN-TM cells. (b) APC generation assay on REN-PECAM-TM and REN-TM
cells confirms surface localization and functional activity of expressed TM. (c)
Mec13/EPCR enhances protein C activation by surface expressed TM on RENPECAM-TM cells. No effect is seen on REN-TM cells, to which the fusion does
not bind. (d) Mec13 scFv and sEPCR (each 150 nM) have no effect on APC
generation on REN-PECAM-TM cells.
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antibodies to PECAM-1 (Figure 4.1). We were interested to determine if TM and
EPCR fusion proteins directed to the same paired epitopes would demonstrate
the same phenomenon.

Indeed, both Mec13 scFv and Mec13 scFv/EPCR

increased the binding of 390 scFv/TM to REN-PECAM cells (Figure 4.5a).
Likewise, 390 scFv and 390 scFv/TM increased the binding of Mec13
scFv/EPCR to these cells (Figure 4.5b).

Mec13 scFv/EPCR enhances protein C activation by 390 scFv/TM on RENPECAM cells
We next studied the activation of protein C on REN-PECAM cells following
dual targeting of scFv/TM and scFv/EPCR fusion proteins. Mec13 scFv/EPCR
demonstrated a dose-dependent enhancement of thrombin-dependent APC
generation in cells also treated with 390 scFv/TM, with nearly ~5-fold increase
seen at the highest dose (Figure 4.6a).
In theory, both enhanced binding and functional partnering between the
TM and EPCR moieties may contribute to the 5-fold increase observed. We
conducted several experiments to determine the relative contribution of each
effect. First, Mec13 scFv (lacking the EPCR moiety) was used to estimate the
“binding effect” and provided ~2-fold stimulation of APC production by 390
scFv/TM (Figure 4.6b). Conversely, we estimated the contribution of enzymatic
partnering (the “EPCR effect”) by using mAb1560 to block the interaction of
EPCR and murine protein C.

In REN-PECAM cells treated with Mec13

scFv/EPCR and 390 scFv/TM, blockade of EPCR reduced APC generation by
~2-fold to almost exactly the level seen in cells co-treated with TM fusion protein
and Mec13 scFv (Figure 4.6b). Taken together, these data reveal two distinct
mechanisms, which make roughly equivalent contributions to the net effect of
Mec13 scFv/EPCR on the generation of APC by 390 scFv/TM.
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Figure 4.5. Mec13 scFv/EPCR and 390 scFv/TM fusion proteins
demonstrate collaborative enhancement of binding
(a) In agreement with experiments done using intact antibodies, Mec13 scFv and
Mec13 scFv/EPCR enhance the binding of 390 scFv/TM and (b) 390 scFv/TM
enhances the binding of Mec13 scFv/EPCR to REN-PECAM cells. Experiments
were done in triplicate (each point shown represents three wells), with SD shown.
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Figure 4.6. Mec13 scFv/EPCR enhances APC generation by 390 scFv/TM
via two distinct mechanisms
(a) Co-treatment of REN-PECAM cells with Mec13 scFv/EPCR produces a dose
dependent increase in APC generation by surface bound 390 scFv/TM. (b)
Additional experiments suggest that two distinct effects contribute to the action of
Mec13 scFv/EPCR fusion protein: 1. an increase in 390 scFv/TM binding and 2.
partnering of cell bound TM and EPCR. The binding effect, demonstrated by cotreatment of cells with 390 scFv/TM and Mec13 scFv (150 nM), is significant (p =
0.004). Likewise, co-treatment with 390 scFv/TM and Mec13 scFv/EPCR results
in significantly greater APC generation (p < 0.001 compared to all other groups)
and is demonstrated to be EPCR-dependent via the use of an anti-EPCR
monoclonal antibody. All experiments were done in triplicate. Data shown are
mean ± SD.
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Dual Targeting on Mouse Endothelial Cells
Mec13 scFv/EPCR enhances protein C activation by 390 scFv/TM on MS1 cells
Using the anti-mTM antibody blockade technique described in Chapter 2,
we measured protein C activation by 390 scFv/TM anchored to MS1 cells, with
and without addition of Mec13 scFv/EPCR. Similar to what had been seen on
REN-PECAM cells, Mec13 scFv/EPCR increased protein C activation by 390
scFv/TM. Likewise, use of Mec13 scFv and EPCR blocking mAb revealed a
similar contribution of two distinct mechanisms by which the EPCR fusion protein
exerts its effect: collaborative enhancement of binding and enzymatic partnering
(Figure 4.7).

Construction and characterization of YN1 scFv/EPCR
We next sought to determine if anchoring TM and EPCR to different
surface molecules would achieve effects similar to what was seen with Mec13
scFv/EPCR and 390 scFv/TM. To test this, we designed and synthesized an
anti-ICAM YN1 scFv/EPCR fusion protein (Figure 4.8a).

We confirmed its

binding to ICAM-expressing cells and its effect on APC generation by TM in a
series of experiments similar to those described above. In this case we utilized
REN-ICAM-TM cells, instead of REN-PECAM-TM cells (Figure 4.8b). Anti-ICAM
scFv/EPCR bound REN-ICAM-TM cells, but not REN-TM cells (Figure 4.8c), and
enhanced protein C activation by membrane TM (Figure 4.8d). Therefore, antiICAM scFv/EPCR displayed binding and functional activity, including TM
partnering, similar to Mec13 scFv/EPCR.

YN1 scFv/EPCR does not enhance protein C activation by 390 scFv/TM
We utilized YN1 scFv/EPCR and 390 scFv/TM fusion proteins to test
anchoring TM and EPCR to different surface molecules. In contrast to Mec13
scFv/EPCR, no enhancement of protein C activation was seen with YN1
scFv/EPCR fusion protein, nor was there any effect of the EPCR blockade
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Figure 4.7. Mec13 scFv/EPCR enhances APC generation by 390 scFv/TM
on antibody blocked MS1 cells
(a) APC generation by 390 scFv/TM was assayed on anti-mTM blocked MS1
cells. The residual activity of endogenous TM is indicated by the dotted line.
Mec13 scFv/EPCR (100 nM) enhances APC generation by cell bound 390
scFv/TM. As seen in REN-PECAM cell experiments, two independent
mechanisms can be discerned: a binding effect (p < 0.001 compared to 390
scFv/TM alone) and an EPCR-dependent effect (p < 0.001 compared to all other
groups). Of note, EPCR blockade slightly reduces the residual activity of
endogenous TM, as indicated by the lower dotted line. Experiments were done
in triplicate. Data shown are mean ± SD.
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Figure 4.8. Construction and characterization of YN1 scFv/EPCR
(a) Molecular design of YN1 scFv/EPCR (b) Western blot of REN-ICAM-TM cells
demonstrates expression of mouse ICAM-1 and TM. (c) Cell-based ELISA
confirms binding of anti-ICAM/TM to REN-ICAM-TM but not REN-TM cells. (d)
YN1 scFv/EPCR enhances activation of protein C by surface expressed TM
when bound to REN-ICAM-TM cells. ELISA and APC generation experiments
done in triplicate, data shown are mean ± SD.
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Figure 4.9. YN1 scFv/EPCR does not enhance protein C activation by 390
scFv/TM on MS1 cells
Anchoring TM and EPCR to different endothelial surface determinants on MS1
cells (PECAM-1 and ICAM-1, respectively), does not enhance APC generation (p
= 0.75). Antibody blockade of EPCR has no effect, other than a small reduction
in the residual activity of endogenous TM. Experiments were done in triplicate;
data shown are mean ± SD.
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Figure 4.10. Dual targeting of Mec13 scFv/EPCR and 390 scFv/TM reduces
pulmonary edema in a mouse model of lung injury
(a) Timeline of intratracheal LPS lung injury model. (b) Pulmonary edema, as
determined by leakage of 125I-labeled albumin from the blood into lung
interstitium and/or alveolar space, is reduced by pre-treatment with 390 scFv/TM.
Co-administration of Mec13 scFv/EPCR, but not anti-ICAM scFv/EPCR,
significantly enhances protection. Pre-treatment with Mec13 scFv/EPCR alone
and co-administration of Mec13 and 390 scFvs have no effect. Data shown are
mean ± SD, with n=4-5 mice in each group. Dotted line indicates level of albumin
leakage seen in control animals that did not receive LPS.
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antibody (Figure 4.9).

In vivo Experiments
Dual targeting of fusion proteins in a mouse model of acute lung injury
Dual targeting of Mec13 scFv/EPCR and 390 scFv/TM was then tested in
a mouse model of lung inflammation/injury and compared to treatment with the
TM fusion protein alone. Pulmonary edema induced by LPS endotoxin challenge
was measured by uptake of IV injected

125

I-labeled albumin. Fusion proteins, or

PBS vehicle, were injected IV 30 minutes prior to LPS challenge (Figure 4.10a).
Dual targeting of Mec13 scFv/EPCR and 390 scFv/TM maximally effectively
reduced pulmonary edema, with a significant improvement compared to
treatment with the TM fusion protein alone. Administration of Mec13 scFv/EPCR
alone had no effect, nor did sequential injection of Mec13 and 390 scFvs. The
latter was done as a control to ensure that the effects on barrier function were not
simply the result of the two antibody fragments binding to PECAM-1. Finally, cotreatment with 390 scFv/TM and YN1 scFv/EPCR resulted in no additional
protection, consistent with our observations on MS1 cells (Figure 4.10b).

III. CONCLUSIONS
This chapter describes an alternate strategy for replicating the enzymatic
partnering seen with endogenous TM and EPCR, namely dual targeting of both
recombinant molecules to the same endothelial surface determinant. As
hypothesized, our in vitro experiments indicate two distinct mechanisms by which
the Mec13 scFv/EPCR enhances the activity of 390 scFv/TM: 1. increased
binding and 2. enzymatic partnering (Figure 4.11).
Interestingly, we find that anchoring TM and EPCR to different endothelial
determinants has no effect.

This result is consistent with the experiments

described in Chapter 1, in which TM and EPCR were co-immobilized on
polyurethane. In those studies, EPCR was found to have an effect only when
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Figure 4.11. Schematic model of dual targeting of scFv/TM and scFv/EPCR
to increase APC production
(a) Normal function of thrombin, TM, EPCR, and PC on the endothelial cell
membrane. Endothelial TM binds thrombin (Factor IIa) and activates protein C.
This process is accelerated by the key co-factor, EPCR, which optimally
positions PC for cleavage. APC can signal to endothelial cells while bound to
EPCR or can bind to protein S and exert anti-coagulant effects, such as the
cleavage of Factor Va. (b) APC generation by surface bound 390 scFv/TM fusion
protein. TM fusion protein anchored to PECAM-1 generates APC, but is unable
to partner with endogenous EPCR. (c) Mec13 scFv increases binding of 390
scFv/TM to PECAM-1 via “collaborative enhancement” mechanism. Increased
binding results in an ~2 fold increase in APC production. (d) Dual targeting of
390 scFv/TM and Mec13 scFv/EPCR. The combination of enhanced binding and
enzymatic partnering between TM and EPCR further increases APC production,
to levels roughly equal to endogenous TM/EPCR.
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the two recombinant proteins were kept in close proximity (< 10 nm)133, and
not with a random, unordered distribution.

Although our experiments on

mouse ECs do not establish a clear cutoff value, it seems likely that some
critical distance exists, beyond which endothelial-anchored TM and EPCR are
no longer sufficiently close to partner efficiently. These results also support
the notion that PECAM-anchored TM may be unable to partner with
endogenous EPCR due to insufficient proximity along the membrane surface.
Apart from its mechanistic significance, dual targeting of TM and EPCR
fusion proteins to paired PECAM-1 epitopes demonstrates enhanced protection
in vivo and could represent a plausible strategy for mitigating acute endothelial
dysfunction in a variety of settings.

IV. MATERIALS AND METHODS
Cell lines
Lysate from the Mec13.3 hybridoma (herein referred to as Mec13) was a
generous gift of Dr. Annunciata Vecchi. MS1 cells were purchased from ATCC
(Manassas, VA) and maintained in DMEM with 10% FBS and 1% antibioticantimycotic (Life technologies, Grand Island, NY).

Antibodies and other reagents
Anti-TM polyclonal antibody (AF3894) was purchased from R&D systems
(Minneapolis, MN).

A second anti-TM polyclonal antibody, used in Western

blotting (sc-7097) was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The anti-EPCR blocking mAb 1560, was supplied by the Esmon laboratory.
HRP-conjugated Anti-FLAG (M2-HRP) antibody was obtained from Sigma
Aldrich (St Louis, MO). HRP-conjugated anti-goat secondary antibody (sc-2056)
was from Santa Cruz Biotechnology. Purified recombinant human protein C was
a generous gift of Dr. Sriram Krishnaswamy.

Bovine thrombin and

lipopolysaccharide (LPS, serotype B4) were purchased from Sigma. APC
substrate, S-2366, was purchased from Diapharma (West Chester, OH).
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Cloning of Mec13 VL and VH cDNAs
Mec13.3 cell lysate in Trizol was extracted with chloroform and phases
were separated by centrifugation. The aqueous phase was removed, mixed with
ethanol, and total RNA was purified using the RNeasy kit (Qiagen, Valencia, CA).
Combined reverse transcription and PCR was performed using SuperScript One
Step RT-PCR kit (Life Technologies, Grand Island, NY). Mec13 light chain was
purified on reducing SDS PAGE and sent for N-terminal (Edman) sequencing at
the UC Davis Proteomics Core Facility. The 7 amino acids identified were used
to design degenerate PCR primers.

Assembly and expression of Mec13 scFv, sEPCR, and Mec13/EPCR constructs
Completed Mec13 VL and VH cDNAs were assembled into a scFv
construct, with VH and VL sequences separated by a (GGGGS)3 linker and a
triple FLAG tag appended to the 3’ end (C-terminus) for purposes of purification
and detection. The extracellular domain of mouse EPCR (sEPCR) was cloned
by PCR from the full-length cDNA described in Chapter 2, and a C-terminal triple
FLAG tag appended.

Finally, the Mec13 scFv/EPCR fusion protein was

constructed with mEPCR on the 5’ end (N-terminus), separated from the Mec13

scFv by an (SSSSG)2AAA linker. All proteins were expressed in S2 cells and
purified using an anti-FLAG affinity column (Sigma Aldrich, St Louis, MO).

Generation of REN-derived stable cell lines
REN-PECAM-TM and REN-ICAM-TM cells. To make cells expressing
both PECAM/TM and ICAM/TM, a mouse TM (mTM) cDNA (containing the entire
coding sequence of mTM and a portion of the 5’ and 3’ UTRs, nt 87-3482) was
purchased from Origene and cloned into the pcDNA3.1/Zeo(-) vector (Life
Technologies, Grand Island, NY).

Since REN-PECAM and REN-ICAM cells

already stably express the Geneticin resistance gene, this expression vector
(which confers resistance to the antibiotic Zeocin) was utilized. Each cell type
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was transfected with Lipofectamine 2000 and selected in media with 250 µg/mL
of Zeocin and 200 µg/mL of Geneticin.

Live cell ELISA assays
ELISAs were performed on live cells as described in Chapters 2 and 3. In
ELISA experiments involving more than one recombinant protein, however, such
as those aimed at measuring collaborative enhancement of binding, anti-FLAGHRP could not be used, as each fusion protein carries a C-terminal triple FLAG
tag. In these cases, detection was via either goat anti-mTM or goat anti-mEPCR
polyclonal antibody, with an anti-goat-HRP secondary antibody. ELISA binding
data was analyzed using PRISM 6.0 software (GraphPad, San Diego, CA).

Protein C ELISA
ELISAs were performed using the same protocol as above, except that
instead of live cells, fusion proteins were bound to protein C immobilized on highbinding plastic wells.

Briefly, wells were incubated overnight at 4°C with a

solution of 4 µg/mL recombinant human protein C in Tris buffered saline (TBS).
Protein C solution was removed and the plate was blocked with 3% BSA solution
for 2 hours. BSA-coated wells with no protein C were used as a control for nonspecific binding.

Protein C activation assays
Generation of APC by scFv/TM fusion was assayed as described in
Chapters 2 and 3.

Briefly, cell monolayers were incubated with various

combinations of TM and EPCR fusion proteins and washed three times with
media prior to the addition of 1nM thrombin and 100nM protein C. In all cases,
protein C activation occurred at 37 °C in assay buf fer (20 mM Tris, 100 mM NaCl,
1 mM CaCl2, 0.1% (w/v) BSA, pH 7.5), and the reaction was stopped by addition
of an excess of hirudin. Anti-mTM antibody blockade and EPCR blockade using
mAb 1560 were performed as described in Chapter 2.
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IT LPS model
Animal studies were carried out in accordance with the Guide for the Care
and Use of Laboratory Animals as adopted by the NIH, under protocols (803320
and 804349) approved by University of Pennsylvania IACUC. The IT LPS model
was performed as described in Chapter 3, with several exceptions.

First, in

some experiments, animals received more than one fusion protein, e.g., scFv/TM
and scFv/EPCR.

Proteins were injected IV in rapid succession, not mixed.

Likewise, bronchoalveolar lavage was not performed in these experiments.

Data analysis and statistics
Results are expressed as mean ± SD unless otherwise noted. Significant
differences between means were determined using Students t-test or one-way
ANOVA followed by appropriate multiple comparison (Tukey) test. P<0.05 was
considered statistically significant.
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CHAPTER FIVE: DISCUSSION AND FUTURE DIRECTIONS

I. LIMITATIONS
The body of work described here is not without limitations. Of greatest
concern is the issue touched upon in Chapter 1, namely that the 390 and YN1
scFv/TM fusion proteins are constructed with the N-terminal lectin domain of TM
adjacent to the scFv moiety (Figure 1.2b).

Although the data presented in

subsequent chapters indicates that this “inverted” conformation does not entirely
preclude the partnering of scFv/TM fusion proteins with endogenous surface
partners (e.g., EPCR) or co-delivered fusion proteins (e.g., scFv/EPCR), it is
likely to have some significant impact on the function of TM, and we have yet to
investigate this possibility in detail. For example, we have only examined the
functional activity of endothelial targeted TM fusion proteins with respect to APC
generation. TM is well known to have numerous other functions, including the
direct neutralization of cytokines via its N-terminal lectin domain and the
activation of TAFI122,161. These activities may be altered or completely absent
given the unnatural conformation of the TM moiety in the current generation of
fusion proteins.
The use of MS1 cells, a transformed pancreatic-derived endothelial cell
line, represents another significant technical limitation of the current body of
work. Immortalized endothelial cells are likely to differ substantially from primary
cultures and/or ECs in vivo, in particular with regard to the precise spatial
relationships between endothelial surface molecules. Moreover, it is plausible
that we have masked some of the significance of these issues via the use of
reagents from several different species -- i.e., bovine thrombin and human PC
zymogen, alongside mouse TM and EPCR.
Finally, the significance of our conclusions must be tempered by the
preliminary nature of the work. We have yet to investigate any cytoprotective
signaling through PAR1 or other receptors, which might be generated by
endothelial targeted TM and EPCR fusion proteins. Since PAR1 is thought to
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localize to the same apical membrane microdomains as EPCR96, it is possible
that PECAM-anchored TM will demonstrate weak cytoprotective signaling
through this receptor. Furthermore, dual targeting of scFv/EPCR fusion protein
to PECAM, which has a significant effect on APC generation, may have little or
no impact on PAR1 signaling.

On the other hand, it is possible that the

requirement for molecular proximity may be less stringent in this case, as APC
generated by TM and/or EPCR fusion proteins might diffuse along the endothelial
surface, bind to endogenous EPCR, and signal through PAR1 in a paracrine
manner.

This intriguing issue clearly merits further investigation.

Likewise,

further characterization is warranted with regards to the in vivo protection offered
by the fusion proteins. IT administration of LPS does not faithfully reproduce all
of the pathological aspects of human lung injury162. Likewise, administration of
fusion protein prior to LPS does not reflect a realistic clinical scenario. A rigorous
appraisal of the benefit/risk ratio of TM and EPCR fusion proteins will need to be
conducted in relevant animal models of human disease, with administration after
the onset of injury. Moreover, we will need to directly test the importance of
TM/EPCR partnering in vivo, before definitively concluding that this factor is
responsible for any differences we observe in the therapeutic efficacy of various
fusion proteins.

II. FUTURE DIRECTIONS
Design of Human PECAM and ICAM-targeted TM Fusion Proteins
To simultaneously address the various technical limitations discussed
above, we have cloned two new scFvs, Ab62163 and R6.5164, which are specific
for human PECAM-1 and ICAM-1, respectively (Figure 5.1a,b). We are in the
process of assembling these into fusion proteins with human TM (hTM). Unlike
the previous generation of mouse specific fusion proteins, we have designed the
scFv/hTM fusion proteins in both available conformations (Figure 5.1c), including
a more natural configuration with the lectin domain free at the N-terminus of the
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molecule. This will allow us to test the significance of the “natural” vs. “inverted”
conformations, not only on the various functions of hTM, but also its partnering
with endogenous surface molecules. The widespread availability of high quality
human primary ECs (e.g., HUVECs and human pulmonary microvascular
endothelial cells, or HPMVECs), will resolve any artifacts related to the use of
immortalized cells. Finally, hTM fusion proteins will be tested using human PC
and thrombin, thus eliminating any issues related to species variation of
reagents.
The use of human ECs will enable testing of signaling pathways and cell
responses not possible with MS1 cells. In particular, HUVECs and HPMVECs
both form tight monolayers and can be used for testing endothelial permeability.
Since both thrombin and APC affect endothelial barrier function through PAR184,
we plan to use permeability assays as an important means of testing the new
hTM fusion proteins and their capacity to influence signaling through this
receptor. Other responses known to depend on APC mediated signaling, e.g.,
the expression of cell-adhesion molecules, will also be examined.
Finally, the use of Ab62 scFv/hTM and R6.5 scFv/hTM fusion proteins
should allow the study of other TM functions, including the potential neutralization
of HMGB1, a damage-associated molecular pattern molecule (DAMP) and
cytokine. HMGB1 is bound and sequestered by the N-terminal lectin domain of
TM and infusion of recombinant sTM has been shown to reduce its plasma
concentration in animal models of systemic inflammation165,166. The N-terminus
of the lectin domain, which is exposed in both soluble and membrane-bound TM,
may be inaccessible on the fusion proteins due to its positioning adjacent to the
scFv moiety. Most importantly, these new scFv/TM fusion proteins will allow preclinical development in primates and, ultimately, testing in human clinical trials if
warranted.
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Figure 5.1. Human PECAM-1 Specific Ab62 scFv
(a) Molecular design of Ab62 scFv, (b) Ab62 scFv binds to human PECAM-1, as
demonstrated by live cell ELISA (done with REN cells transfected with human
PECAM-1) and immunofluorescence of HUVECs. Strong staining seen at cellcell junctions is typical for PECAM-1. (c) Fusion of Ab62 scFv with human TM in
both conformations, for testing of lectin and EGF domain function.
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Strategies to Define and Improve Endothelial Targeting
One aspect of the endothelial targeted TM fusion proteins that remains
poorly characterized is their ability to target the endothelium in vivo. Although
initial experiments indicated that 390 scFv/TM effectively targets the lung
following intravenous injection127, subsequent efforts have failed to confirm
thisresult. Likewise, the biodistribution of YN1 scFv/TM, which has been more
rigorously characterized, indicates very weak targeting to lung endothelium. This
result was somewhat unexpected, given the robust targeting of the parental mAb
(Figure 5.2), and the fact that the scFv/TM fusion proteins are large enough to
escape the rapid renal clearance seen with free scFvs.
There are multiple possible explanations for these findings.

First, the

scFv/TM fusion proteins are monovalent, and the decreased avidity, as
compared to mAbs, could have a drastic effect on their ability to anchor
themselves to the endothelium under the flow conditions present in the
vasculature. Second, TM may mediate uptake or clearance of fusion proteins by
the liver and spleen.

Third, scFv/TM fusion proteins lack Fc domains and

therefore are incapable of recycling through the neonatal Fc receptor (FcRn),
which markedly prolongs the circulation time of mAbs167. Finally, there is some
evidence that even bivalent engagement of ICAM-1 may induce internalization by
ECs, meaning that some component of the lung biodistribution of YN1 mAb may
reflect intracellular, rather than surface bound antibody168. Of note, this latter
possibility differs from the others in that it would be a potential negative for
endothelial targeting of TM, which requires surface localization.
To investigate these possibilities, we are in the process of designing and
testing several new constructs.

In particular, we are collaborating with the

Tsourkas laboratory in the Department of Bioengineering to develop a means of
site-specific

conjugation

of

TM

to

anti-PECAM

and

anti-ICAM

mAbs.

Conventional mAb conjugation, which utilizes non-specific chemistry, is limited by
poor efficiency, the possibility of impaired mAb or cargo (i.e. TM) function, and
the inability to limit or precisely control conjugate size. The introduction of site
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specific modifications on the mAb and TM moieties, however, allows the use of
highly efficient click chemistry, results in predictable orientation of the
components, and enables the incorporation of only one mAb and TM into each
conjugate (Figure 5.3). Using this new technology, we plan to test the role of
each of the above factors (avidity, TM clearance, FcRn recycling, and
internalization) in determining biodistribution to the lung and other organs. Better
understanding of these variables should allow the eventual design of TM
therapeutics with improved endothelial targeting.
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Figure 5.2. Biodistribution of YN1 scFv/TM and YN1 mAb in vivo
(a) Biodistribution of YN1 scFv/TM at 30 min post-injection shows weak, but
specific targeting to the lung, based on comparison to sTM and testing in ICAM-/mice. (b) Lung targeting of YN1 scFv/TM is an order of magnitude weaker than
parental mAb.
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Figure 5.3. Design of site-specific mAb/sTM conjugates
Conventional bioconjugation is limited by potential disruption of mAb and sTM
function, as well as inability to control the size of the resulting conjugate. Sitespecific conjugation, in contrast, allows 1:1 incorporation with defined orientation
of the individual components.
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